1
|
Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y. Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene 2024; 43:1317. [PMID: 38418546 DOI: 10.1038/s41388-024-02990-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2024]
Affiliation(s)
- C -R Pradeep
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
- Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA
| | - A Zeisel
- Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
| | - W J Köstler
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
- Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - M Lauriola
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - J Jacob-Hirsch
- Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - B Haibe-Kains
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
- Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium
| | - N Amariglio
- Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - N Ben-Chetrit
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - A Emde
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - I Solomonov
- Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel
| | - G Neufeld
- Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
| | - M Piccart
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
| | - I Sagi
- Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel
| | - C Sotiriou
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
| | - G Rechavi
- Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Domany
- Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
| | - C Desmedt
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
| | - Y Yarden
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
| |
Collapse
|
2
|
Masalha M, Meningher T, Mizrahi A, Barzilai A, Tabibian-Keissar H, Gur-Wahnon D, Ben-Dov IZ, Kapenhas J, Jacob-Hirsch J, Leibowitz R, Sidi Y, Avni D. MiR-199a-3p Induces Mesenchymal to Epithelial Transition of Keratinocytes by Targeting RAP2B. Int J Mol Sci 2022; 23:ijms232315401. [PMID: 36499729 PMCID: PMC9741271 DOI: 10.3390/ijms232315401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 11/27/2022] [Accepted: 11/29/2022] [Indexed: 12/13/2022] Open
Abstract
Cutaneous squamous cell carcinoma (CSCC) is an epidermal skin cancer that evolves from normal epidermis along several pre-malignant stages. Previously we found specific miRNAs alterations in each step along these stages. miR-199a-3p expression decreases at the transition to later stages. A crucial step for epithelial carcinoma cells to acquire invasive capacity is the disruption of cell-cell contacts and the gain of mesenchymal motile phenotype, a process known as epithelial-to-mesenchymal transition (EMT). This study aims to study the role of decreased expression of miR-199a-3p in keratinocytes' EMT towards carcinogenesis. First, we measured miR-199a-3p in different stages of epidermal carcinogenesis. Then, we applied Photoactivatable Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation (PAR-CLIP) assay to search for possible biochemical targets of miR-199a-3p and verified that Ras-associated protein B2 (RAP2B) is a bona-fide target of miR-199a-3p. Next, we analyzed RAP2B expression, in CSCC biopsies. Last, we evaluated possible mechanisms leading to decreased miR-199a-3p expression. miR-199a-3p induces a mesenchymal to epithelial transition (MET) in CSSC cells. Many of the under-expressed genes in CSCC overexpressing miR-199a-3p, are possible targets of miR-199a-3p and play roles in EMT. RAP2B is a biochemical target of miR-199a-3p. Overexpression of miR-199a-3p in CSCC results in decreased phosphorylated focal adhesion kinase (FAK). In addition, inhibiting FAK phosphorylation inhibits EMT marker genes' expression. In addition, we proved that DNA methylation is part of the mechanism by which miR-199a-3p expression is inhibited. However, it is not by the methylation of miR-199a putative promoter. These findings suggest that miR-199a-3p inhibits the EMT process by targeting RAP2B. Inhibitors of RAP2B or FAK may be effective therapeutic agents for CSCC.
Collapse
Affiliation(s)
- Moamen Masalha
- Laboratory of Molecular Cell Biology, Center for Cancer Research, Department of Medicine C, Sheba Medical Center, Tel Hashomer 52621, Israel
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Tal Meningher
- Laboratory of Molecular Cell Biology, Center for Cancer Research, Department of Medicine C, Sheba Medical Center, Tel Hashomer 52621, Israel
| | - Adi Mizrahi
- Laboratory of Molecular Cell Biology, Center for Cancer Research, Department of Medicine C, Sheba Medical Center, Tel Hashomer 52621, Israel
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Aviv Barzilai
- Department of Dermatology, Institute of Pathology Sheba Medical Center, Tel Hashomer 52621, Israel
| | | | - Devorah Gur-Wahnon
- Laboratory of Medical Transcriptomics, Nephrology and Hypertension Services, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Iddo Z. Ben-Dov
- Laboratory of Medical Transcriptomics, Nephrology and Hypertension Services, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Joshua Kapenhas
- Laboratory of Molecular Cell Biology, Center for Cancer Research, Department of Medicine C, Sheba Medical Center, Tel Hashomer 52621, Israel
| | | | - Raya Leibowitz
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
- Oncology institute, Shamir Medical Center, Zerifin 70300, Israel
| | - Yechezkel Sidi
- Laboratory of Molecular Cell Biology, Center for Cancer Research, Department of Medicine C, Sheba Medical Center, Tel Hashomer 52621, Israel
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Dror Avni
- Laboratory of Molecular Cell Biology, Center for Cancer Research, Department of Medicine C, Sheba Medical Center, Tel Hashomer 52621, Israel
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
- Correspondence: ; Tel.: +972-3-5307479
| |
Collapse
|
3
|
Eytan K, Versano Z, Oren R, Jacob-Hirsch J, Leitner M, Harmelin A, Rechavi G, Toren A, Paglin S, Yalon M. Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant. Front Oncol 2022; 12:959133. [PMID: 36091130 PMCID: PMC9462064 DOI: 10.3389/fonc.2022.959133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 08/01/2022] [Indexed: 11/16/2022] Open
Abstract
We found that pediatric glioblastoma (PED-GBM) cell lines from diffuse intrinsic pontine glioma (DIPG) carrying the H3K27M mutation or from diffuse hemispheric glioma expressing the H3G34R mutation are sensitive to the combination of vorinostat (a histone deacetylase inhibitor) and PARP-1 inhibitors. The combined treatment increased the phosphorylation of eIF2α (P-eIF2α) relative to each drug alone and enhanced the decrease in cell survival. To explore the role played by increased P-eIF2α in modulating PED-GBM survival and response to treatments, we employed brain-penetrating inhibitors of P-eIF2α dephosphorylation: salubrinal and raphin-1. These drugs increased P-eIF2α, DNA damage, and cell death, similarly affecting the sensitivity of DIPG cells and derived neurospheres to PARP-1 inhibitors. Interestingly, these drugs also decreased the level of eIF2Bϵ (the catalytic subunit of eIF2B) and increased its phosphorylation, thereby enhancing the effect of increased P-eIF2α. Transient transfection with the S51D phosphomimetic eIF2α variant recapitulated the effect of salubrinal and raphin-1 on PED-GBM survival and sensitivity to PARP-1 inhibitors. Importantly, either salubrinal or raphin-1 dramatically increased the sensitivity of DIPG cells to radiation, the main treatment modality of PED-GBM. Finally, PED-GBM was more sensitive than normal human astrocytes to salubrinal, raphin-1, and the treatment combinations described herein. Our results indicate that combinations of histone deacetylase inhibitors and PARP-1 inhibitors should be evaluated for their toxicity and efficacy in PED-GBM patients and point to drugs that increase P-eIF2α or modulate its downstream effectors as a novel means of treating PED-GBM.
Collapse
Affiliation(s)
- Karin Eytan
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
| | - Ziv Versano
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Roni Oren
- Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel
| | - Jasmine Jacob-Hirsch
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Moshe Leitner
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
| | - Alon Harmelin
- Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel
| | - Gideon Rechavi
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Amos Toren
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Shoshana Paglin
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
| | - Michal Yalon
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
- Chaim Sheba Medical Center, Ramat Gan, Israel
- *Correspondence: Michal Yalon,
| |
Collapse
|
4
|
Moyal L, Arkin C, Gorovitz-Haris B, Querfeld C, Rosen S, Knaneh J, Amitay-Laish I, Prag-Naveh H, Jacob-Hirsch J, Hodak E. Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden. Br J Dermatol 2021; 185:999-1012. [PMID: 34053079 DOI: 10.1111/bjd.20519] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/24/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND Literature regarding exosomes as mediators in intercellular communication to promote progression in mycosis fungoides (MF) is lacking. OBJECTIVES To characterize MF-derived exosomes and their involvement in the disease. METHODS Exosomes were isolated by ultracentrifugation from cutaneous T-cell lymphoma (CTCL) cell lines, and from plasma of patients with MF and controls (healthy individuals). Exosomes were confirmed by electron microscopy, NanoSight and CD81 staining. Cell-line exosomes were profiled for microRNA array. Exosomal microRNA (exomiRNA) expression and uptake, and plasma-cell-free microRNA (cfmiRNA) were analysed by reverse-transcriptase quantitative polymerase chain reaction. Exosome uptake was monitored by fluorescent labelling and CD81 immunostaining. Migration was analysed by transwell migration assay. RESULTS MyLa- and MJ-derived exosomes had a distinctive microRNA signature with abundant microRNA (miR)-155 and miR-1246. Both microRNAs were delivered into target cells, but only exomiR-155 was tested, demonstrating a migratory effect on target cells. Plasma levels of cfmiR-1246 were significantly highest in combined plaque/tumour MF, followed by patch MF, and were lowest in controls (plaque/tumour > patch > healthy), while cfmiR-155 was upregulated only in plaque/tumour MF vs. controls. Specifically, exomiR-1246 (and not exomiR-155) was higher in plasma of plaque/tumour MF than in healthy controls. Plasma exosomes from MF but not from controls increased cell migration. CONCLUSIONS Our findings show that MF-derived exosomes promote cell motility and are enriched with miR-155, a well-known microRNA in MF, and miR-1246, not previously reported in MF. Based on their plasma expression we suggest that they may serve as potential biomarkers for tumour burden.
Collapse
Affiliation(s)
- L Moyal
- Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva, 4941492, Israel.,Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - C Arkin
- Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - B Gorovitz-Haris
- Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva, 4941492, Israel.,Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - C Querfeld
- Department of Pathology & Division of Dermatology, City of Hope, and Beckman Research Institute, Duarte, CA, USA
| | - S Rosen
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.,Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
| | - J Knaneh
- Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - I Amitay-Laish
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - H Prag-Naveh
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - J Jacob-Hirsch
- Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel
| | - E Hodak
- Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva, 4941492, Israel.,Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4941492, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel
| |
Collapse
|
5
|
Brand H, Barnabas GD, Sapoznik S, Bahar-Shany K, Pozniak Y, Yung Y, Hourvitz A, Geiger T, Jacob-Hirsch J, Levanon K. NF-κB-miR-155 axis activation mediates ovulation-induced oncogenic effects in fallopian tube epithelium. Carcinogenesis 2021; 41:1703-1712. [PMID: 32614381 DOI: 10.1093/carcin/bgaa068] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 06/15/2020] [Accepted: 06/24/2020] [Indexed: 02/06/2023] Open
Abstract
The fallopian tube secretory epithelial cells (FTSECs) are the cell-of-origin of most high-grade serous ovarian carcinomas (HGSOC). FTSECs are repeatedly exposed to inflammation induced by follicular fluid (FF) that is released with every ovulation cycle throughout a woman's reproductive years. Uninterrupted ovulation cycles are an established risk factor for HGSOC. Stimuli present in the FF induce an inflammatory environment which may cause DNA damage eventually leading to serous tumorigenesis. With the aim of elucidating possible mechanistic pathways, we established an 'ex vivo persistent ovulation model' mimicking the repeated exposure of human benign fallopian tube epithelium (FTE) to FF. We performed mass spectrometry analysis of the secretome of the ex vivo cultures as well as confirmatory targeted expressional and functional analyses. We demonstrated activation of the NF-κB pathway and upregulation of miR-155 following short-term exposure of FTE to human FF. Increased expression of miR-155 was also detected in primary HGSOC tumors compared with benign primary human FTE and corresponded with changes in the expression of miR-155 target genes. The phenotype of miR-155 overexpression in FTSEC cell line is of increased migratory and altered adhesion capacities. Overall, activation of the NF-κB-miR-155 axis in FTE may represent a possible link between ovulation-induced inflammation, DNA damage, and transcriptional changes that may eventually lead to serious carcinogenesis.
Collapse
Affiliation(s)
- Hadar Brand
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.,Sackler Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| | - Georgina D Barnabas
- Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| | - Stav Sapoznik
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Keren Bahar-Shany
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Yair Pozniak
- Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| | - Yuval Yung
- IVF Unit and Reproduction Lab, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Ariel Hourvitz
- Sackler Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.,IVF Unit and Reproduction Lab, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Tamar Geiger
- Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| | | | - Keren Levanon
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.,Sackler Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| |
Collapse
|
6
|
Friedman N, Jacob-Hirsch J, Drori Y, Eran E, Kol N, Nayshool O, Mendelson E, Rechavi G, Mandelboim M. Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells. PLoS One 2021; 16:e0247128. [PMID: 33630927 PMCID: PMC7906355 DOI: 10.1371/journal.pone.0247128] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 02/01/2021] [Indexed: 12/15/2022] Open
Abstract
Human coronaviruses (HCoVs) cause mild to severe respiratory infection. Most of the common cold illnesses are caused by one of four HCoVs, namely HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43. Several studies have applied global transcriptomic methods to understand host responses to HCoV infection, with most studies focusing on the pandemic severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome CoV (MERS-CoV) and the newly emerging SARS-CoV-2. In this study, Next Generation Sequencing was used to gain new insights into cellular transcriptomic changes elicited by alphacoronavirus HCoV-229E. HCoV-229E-infected MRC-5 cells showed marked downregulation of superpathway of cholesterol biosynthesis and eIF2 signaling pathways. Moreover, upregulation of cyclins, cell cycle control of chromosomal replication, and the role of BRCA1 in DNA damage response, alongside downregulation of the cell cycle G1/S checkpoint, suggest that HCoV-229E may favors S phase for viral infection. Intriguingly, a significant portion of key factors of cell innate immunity, interferon-stimulated genes (ISGs) and other transcripts of early antiviral response genes were downregulated early in HCoV-229E infection. On the other hand, early upregulation of the antiviral response factor Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) was observed. APOBEC3B cytidine deaminase signature (C-to-T) was previously observed in genomic analysis of SARS-CoV-2 but not HCoV-229E. Higher levels of C-to-T mutations were found in countries with high mortality rates caused by SARS-CoV-2. APOBEC activity could be a marker for new emerging CoVs. This study will enhance our understanding of commonly circulating HCoVs and hopefully provide critical information about still-emerging coronaviruses.
Collapse
Affiliation(s)
- Nehemya Friedman
- Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Jasmine Jacob-Hirsch
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Yaron Drori
- Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Eyal Eran
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Nitzan Kol
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Omri Nayshool
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Ella Mendelson
- Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Gideon Rechavi
- Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel
- Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Michal Mandelboim
- Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- * E-mail:
| |
Collapse
|
7
|
Alon S, Eisenberg E, Jacob-Hirsch J, Rechavi G, Vatine G, Toyama R, Coon SL, Klein DC, Gothilf Y. Corrigendum to: A new cis-acting regulatory element driving gene expression in the zebrafish pineal gland. Bioinformatics 2019; 35:4206. [DOI: 10.1093/bioinformatics/btz410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Shukrun R, Golan H, Caspi R, Pode-Shakked N, Pleniceanu O, Vax E, Bar-Lev DD, Pri-Chen S, Jacob-Hirsch J, Schiby G, Harari-Steinberg O, Mark-Danieli M, Dekel B, Toren A. NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target. Oncogenesis 2019; 8:48. [PMID: 31477684 PMCID: PMC6718423 DOI: 10.1038/s41389-019-0156-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 04/22/2019] [Accepted: 05/06/2019] [Indexed: 12/20/2022] Open
Abstract
Pleuropulmonary blastoma (PPB) is a rare pediatric lung neoplasm that recapitulates developmental pathways of early embryonic lungs. As lung development proceeds with highly regulated mesenchymal-epithelial interactions, a DICER1 mutation in PPB generates a faulty lung differentiation program with resultant biphasic tumors composed of a primitive epithelial and mesenchymal stroma with early progenitor blastomatous cells. Deciphering of PPB progression has been hampered by the difficulty of culturing PPB cells, and specifically progenitor blastomatous cells. Here, we show that in contrast with in-vitro culture, establishment of PPB patient-derived xenograft (PDX) in NOD-SCID mice selects for highly proliferating progenitor blastoma overexpressing critical regulators of lung development and multiple imprinted genes. These stem-like tumors were sequentially interrogated by gene profiling to show a FGF module that is activated alongside Neural cell adhesion molecule 1 (NCAM1). Targeting the progenitor blastoma and these transitions with an anti-NCAM1 immunoconjugate (Lorvotuzumab mertansine) inhibited tumor growth and progression providing new paradigms for PPB therapeutics. Altogether, our novel in-vivo PPB xenograft model allowed us to enrich for highly proliferating stem-like cells and to identify FGFR and NCAM1 as two key players that can serve as therapeutic targets in this poorly understood and aggressive disease.
Collapse
Affiliation(s)
- Rachel Shukrun
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel
| | - Hana Golan
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Pediatric Hematology Oncology Research Laboratory, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Revital Caspi
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel
| | - Naomi Pode-Shakked
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Sheba Medical Center, Tel Hashomer, 5262000, Ramat-Gan, Israel
| | - Oren Pleniceanu
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel
| | - Einav Vax
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel
| | - Dekel D Bar-Lev
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Sara Pri-Chen
- The Maurice and Gabriela Goldschleger Eye Research Institute, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Jasmine Jacob-Hirsch
- Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Cancer Research Center and the Wohl Institute of Translational Medicine, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Ginette Schiby
- Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Department of Pathology, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Orit Harari-Steinberg
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Michal Mark-Danieli
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| | - Benjamin Dekel
- Pediatric Stem Cell Research Institute, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel. .,Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. .,Division of Pediatric Nephrology, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel.
| | - Amos Toren
- Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Pediatric Hematology Oncology Research Laboratory, Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat-Gan, Israel
| |
Collapse
|
9
|
Golan H, Shukrun R, Caspi R, Vax E, Pode-Shakked N, Goldberg S, Pleniceanu O, Bar-Lev DD, Mark-Danieli M, Pri-Chen S, Jacob-Hirsch J, Kanter I, Trink A, Schiby G, Bilik R, Kalisky T, Harari-Steinberg O, Toren A, Dekel B. In Vivo Expansion of Cancer Stemness Affords Novel Cancer Stem Cell Targets: Malignant Rhabdoid Tumor as an Example. Stem Cell Reports 2018; 11:795-810. [PMID: 30122444 PMCID: PMC6135722 DOI: 10.1016/j.stemcr.2018.07.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2017] [Revised: 07/21/2018] [Accepted: 07/23/2018] [Indexed: 12/14/2022] Open
Abstract
Cancer stem cell (CSC) identification relies on transplantation assays of cell subpopulations sorted from fresh tumor samples. Here, we attempt to bypass limitations of abundant tumor source and predetermined immune selection by in vivo propagating patient-derived xenografts (PDX) from human malignant rhabdoid tumor (MRT), a rare and lethal pediatric neoplasm, to an advanced state in which most cells behave as CSCs. Stemness is then probed by comparative transcriptomics of serial PDXs generating a gene signature of epithelial to mesenchymal transition, invasion/motility, metastasis, and self-renewal, pinpointing putative MRT CSC markers. The relevance of these putative CSC molecules is analyzed by sorting tumorigenic fractions from early-passaged PDX according to one such molecule, deciphering expression in archived primary tumors, and testing the effects of CSC molecule inhibition on MRT growth. Using this platform, we identify ALDH1 and lysyl oxidase (LOX) as relevant targets and provide a larger framework for target and drug discovery in rare pediatric cancers. Human malignant rhabdoid tumor (MRT) can be propagated in vivo as tumor xenografts Long-term propagated PDX enrich for CSC frequency with no need for immune selection Distinct gene signature in stem-like MRT xenografts reveals putative CSC biomarkers Screening of putative CSC biomarkers allows identification of therapeutic targets
Collapse
Affiliation(s)
- Hana Golan
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Division of Pediatric Hemato-oncology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Rachel Shukrun
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Revital Caspi
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Einav Vax
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Naomi Pode-Shakked
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Sanja Goldberg
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel
| | - Oren Pleniceanu
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Dekel D Bar-Lev
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel
| | - Michal Mark-Danieli
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel
| | - Sara Pri-Chen
- The Maurice and Gabriela Goldschleger Eye Research Institute, Sheba Medical Center, Ramat-Gan 52621, Israel
| | - Jasmine Jacob-Hirsch
- Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel
| | - Itamar Kanter
- Faculty of Engineering and Nanotechnology Institute, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - Ariel Trink
- Faculty of Engineering and Nanotechnology Institute, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - Ginette Schiby
- Department of Pathology, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Ron Bilik
- Department of Pediatric Surgery, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan 52621, Israel
| | - Tomer Kalisky
- Faculty of Engineering and Nanotechnology Institute, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - Orit Harari-Steinberg
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Amos Toren
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Division of Pediatric Hemato-oncology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Benjamin Dekel
- Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat-Gan 52621, Israel; Division of Pediatric Nephrology, Safra Children's Hospital, Sheba Medical Center, Ramat-Gan 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
| |
Collapse
|
10
|
Jacob-Hirsch J, Eyal E, Knisbacher BA, Roth J, Cesarkas K, Dor C, Farage-Barhom S, Kunik V, Simon AJ, Gal M, Yalon M, Moshitch-Moshkovitz S, Tearle R, Constantini S, Levanon EY, Amariglio N, Rechavi G. Whole-genome sequencing reveals principles of brain retrotransposition in neurodevelopmental disorders. Cell Res 2018; 28:187-203. [PMID: 29327725 DOI: 10.1038/cr.2018.8] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 11/10/2017] [Accepted: 11/20/2017] [Indexed: 02/07/2023] Open
Abstract
Neural progenitor cells undergo somatic retrotransposition events, mainly involving L1 elements, which can be potentially deleterious. Here, we analyze the whole genomes of 20 brain samples and 80 non-brain samples, and characterized the retrotransposition landscape of patients affected by a variety of neurodevelopmental disorders including Rett syndrome, tuberous sclerosis, ataxia-telangiectasia and autism. We report that the number of retrotranspositions in brain tissues is higher than that observed in non-brain samples and even higher in pathologic vs normal brains. The majority of somatic brain retrotransposons integrate into pre-existing repetitive elements, preferentially A/T rich L1 sequences, resulting in nested insertions. Our findings document the fingerprints of encoded endonuclease independent mechanisms in the majority of L1 brain insertion events. The insertions are "non-classical" in that they are truncated at both ends, integrate in the same orientation as the host element, and their target sequences are enriched with a CCATT motif in contrast to the classical endonuclease motif of most other retrotranspositions. We show that L1Hs elements integrate preferentially into genes associated with neural functions and diseases. We propose that pre-existing retrotransposons act as "lightning rods" for novel insertions, which may give fine modulation of gene expression while safeguarding from deleterious events. Overwhelmingly uncontrolled retrotransposition may breach this safeguard mechanism and increase the risk of harmful mutagenesis in neurodevelopmental disorders.
Collapse
Affiliation(s)
- Jasmine Jacob-Hirsch
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel.,Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Israel
| | - Eran Eyal
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | | | - Jonathan Roth
- Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel Aviv Medical Center, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Karen Cesarkas
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Chen Dor
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Sarit Farage-Barhom
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Vered Kunik
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Amos J Simon
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Moran Gal
- Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Israel
| | - Michal Yalon
- Department of Pediatric Hematology-Oncology, Edmond and Lily Safra Children's Hospital, The Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Sharon Moshitch-Moshkovitz
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Rick Tearle
- Complete Genomics, 2071 Stierlin Court, Mountain View, CA 94043, USA
| | - Shlomi Constantini
- Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel Aviv Medical Center, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Erez Y Levanon
- Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Israel
| | - Ninette Amariglio
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel.,Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Israel
| | - Gideon Rechavi
- Cancer Research Center and the Wohl Institute of Translational Medicine, the Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
11
|
Mizrahi A, Barzilai A, Gur-Wahnon D, Ben-Dov IZ, Glassberg S, Meningher T, Elharar E, Masalha M, Jacob-Hirsch J, Tabibian-Keissar H, Barshack I, Roszik J, Leibowitz-Amit R, Sidi Y, Avni D. Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. Oncogene 2017; 37:218-230. [PMID: 28925390 DOI: 10.1038/onc.2017.315] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Revised: 07/05/2017] [Accepted: 07/31/2017] [Indexed: 12/18/2022]
Abstract
Skin carcinogenesis is known to be a multi-step process with several stages along its malignant evolution. We hypothesized that transformation of normal epidermis to cutaneous squamous cell carcinoma (cSCC) is causally linked to alterations in microRNAs (miRNA) expression. For this end we decided to evaluate their alterations in the pathologic states ending in cSCC. Total RNA was extracted from formalin fixed paraffin embedded biopsies of five stages along the malignant evolution of keratinocytes towards cSCC: Normal epidermis, solar elastosis, actinic keratosis KIN1-2, advanced actinic keratosis KIN3 and well-differentiated cSCC. Next-generation small RNA sequencing was performed. We found that 18 miRNAs are overexpressed and 28 miRNAs are underexpressed in cSCC compared to normal epidermis. miR-424, miR-320, miR-222 and miR-15a showed the highest fold change among the overexpressed miRNAs. And miR-100, miR-101 and miR-497 showed the highest fold change among the underexpressed miRNAs. Heat map of hierarchical clustering analysis of significantly changed miRNAs and principle component analysis disclosed that the most prominent change in miRNAs expression occurred in the switch from 'early' stages; normal epidermis, solar elastosis and early actinic keratosis to the 'late' stages of epidermal carcinogenesis; late actinic keratosis and cSCC. We found several miRNAs with 'stage specific' alterations while others display a clear 'gradual', either progressive increase or decrease in expression along the malignant evolution of keratinocytes. The observed alterations focused in miRNAs involved in the regulation of AKT/mTOR or in those involved in epithelial to mesenchymal transition. We chose to concentrate on the evaluation of the molecular role of miR-497. We found that it induces reversion of epithelial to mesenchymal transition. We proved that SERPINE-1 is its biochemical target. The present study allows us to further study the pathways that are regulated by miRNAs along the malignant evolution of keratinocytes towards cSCC.
Collapse
Affiliation(s)
- A Mizrahi
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel
| | - A Barzilai
- Department of Dermatology and Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel
| | - D Gur-Wahnon
- Laboratory of Medical Transcriptomics, Nephrology and Hypertension Services, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - I Z Ben-Dov
- Laboratory of Medical Transcriptomics, Nephrology and Hypertension Services, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - S Glassberg
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel
| | - T Meningher
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel
| | - E Elharar
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel
| | - M Masalha
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel.,Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - J Jacob-Hirsch
- Center for Cancer Research, Sheba Medical Center, Tel Hashomer, Israel
| | - H Tabibian-Keissar
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.,Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel
| | - I Barshack
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel
| | - J Roszik
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - R Leibowitz-Amit
- Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel
| | - Y Sidi
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel.,Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - D Avni
- Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel
| |
Collapse
|
12
|
Zayoud M, Marcu-Malina V, Vax E, Jacob-Hirsch J, Elad-Sfadia G, Barshack I, Kloog Y, Goldstein I. Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. Front Immunol 2017; 8:799. [PMID: 28736556 PMCID: PMC5500629 DOI: 10.3389/fimmu.2017.00799] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Accepted: 06/23/2017] [Indexed: 11/29/2022] Open
Abstract
The Ras family of GTPases plays an important role in signaling nodes downstream to T cell receptor and CD28 activation, potentially lowering the threshold for T-cell receptor activation by autoantigens. Somatic mutation in NRAS or KRAS may cause a rare autoimmune disorder coupled with abnormal expansion of lymphocytes. T cells from rheumatoid arthritis (RA) patients show excessive activation of Ras/MEK/ERK pathway. The small molecule farnesylthiosalicylic acid (FTS) interferes with the interaction between Ras GTPases and their prenyl-binding chaperones to inhibit proper plasma membrane localization. In the present study, we tested the therapeutic and immunomodulatory effects of FTS and its derivative 5-fluoro-FTS (F-FTS) in the rat adjuvant-induced arthritis model (AIA). We show that AIA severity was significantly reduced by oral FTS and F-FTS treatment compared to vehicle control treatment. FTS was as effective as the mainstay anti-rheumatic drug methotrexate, and combining the two drugs significantly increased efficacy compared to each drug alone. We also discovered that FTS therapy inhibited both the CFA-driven in vivo induction of Th17 and IL-17/IFN-γ producing “double positive” as well as the upregulation of serum levels of the Th17-associated cytokines IL-17A and IL-22. By gene microarray analysis of effector CD4+ T cells from CFA-immunized rats, re-stimulated in vitro with the mycobacterium tuberculosis heat-shock protein 65 (Bhsp65), we determined that FTS abrogated the Bhsp65-induced transcription of a large list of genes (e.g., Il17a/f, Il22, Ifng, Csf2, Lta, and Il1a). The functional enrichment bioinformatics analysis showed significant overlap with predefined gene sets related to inflammation, immune system processes and autoimmunity. In conclusion, FTS and F-FTS display broad immunomodulatory effects in AIA with inhibition of the Th17-type response to a dominant arthritogenic antigen. Hence, targeting Ras signal-transduction cascade is a potential novel therapeutic approach for RA.
Collapse
Affiliation(s)
- Morad Zayoud
- Sheba Cancer Research Center, Chaim Sheba Academic Medical Center, Ramat Gan, Israel.,Rheumatology Unit, Chaim Sheba Academic Medical Center, Ramat Gan, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Victoria Marcu-Malina
- Sheba Cancer Research Center, Chaim Sheba Academic Medical Center, Ramat Gan, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Einav Vax
- Sheba Cancer Research Center, Chaim Sheba Academic Medical Center, Ramat Gan, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Jasmine Jacob-Hirsch
- Sheba Cancer Research Center, Chaim Sheba Academic Medical Center, Ramat Gan, Israel
| | - Galit Elad-Sfadia
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences & Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel
| | - Iris Barshack
- Institute of Pathology, Chaim Sheba Academic Medical Center, Ramat Gan, Israel
| | - Yoel Kloog
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences & Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel
| | - Itamar Goldstein
- Sheba Cancer Research Center, Chaim Sheba Academic Medical Center, Ramat Gan, Israel.,Rheumatology Unit, Chaim Sheba Academic Medical Center, Ramat Gan, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| |
Collapse
|
13
|
Ben-Shoshan SO, Kagan P, Sultan M, Barabash Z, Dor C, Jacob-Hirsch J, Harmelin A, Pappo O, Marcu-Malina V, Ben-Ari Z, Amariglio N, Rechavi G, Goldstein I, Safran M. ADAR1 deletion induces NFκB and interferon signaling dependent liver inflammation and fibrosis. RNA Biol 2016; 14:587-602. [PMID: 27362366 DOI: 10.1080/15476286.2016.1203501] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Adenosine deaminase acting on RNA (ADAR) 1 binds and edits double-stranded (ds) RNA secondary structures found mainly within untranslated regions of many transcripts. In the current research, our aim was to study the role of ADAR1 in liver homeostasis. As previous studies show a conserved immunoregulatory function for ADAR1 in mammalians, we focused on its role in preventing chronic hepatic inflammation and the associated activation of hepatic stellate cells to produce extracellular matrix and promote fibrosis. We show that hepatocytes specific ADAR1 knock out (KO) mice display massive liver damage with multifocal inflammation and fibrogenesis. The bioinformatics analysis of the microarray gene-expression datasets of ADAR1 KO livers reveled a type-I interferons signature and an enrichment for immune response genes compared to control littermate livers. Furthermore, we found that in vitro silencing of ADAR1 expression in HepG2 cells leads to enhanced transcription of NFκB target genes, foremost of the pro-inflammatory cytokines IL6 and IL8. We also discovered immune cell-independent paracrine signaling among ADAR1-depleted HepG2 cells and hepatic stellate cells, leading to the activation of the latter cell type to adopt a profibrogenic phenotype. This paracrine communication dependent mainly on the production and secretion of the cytokine IL6 induced by ADAR1 silencing in hepatocytes. Thus, our findings shed a new light on the vital regulatory role of ADAR1 in hepatic immune homeostasis, chiefly its inhibitory function on the crosstalk between the NFκB and type-I interferons signaling cascades, restraining the development of liver inflammation and fibrosis.
Collapse
Affiliation(s)
- Shirley Oren Ben-Shoshan
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,d Sackler Faculty of Medicine , Tel Aviv University , Israel
| | - Polina Kagan
- b Liver Research Laboratory , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,d Sackler Faculty of Medicine , Tel Aviv University , Israel
| | - Maya Sultan
- b Liver Research Laboratory , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel
| | - Zohar Barabash
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel
| | - Chen Dor
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel
| | - Jasmine Jacob-Hirsch
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,e The Mina and Everard Goodman Faculty of Life Sciences , Bar Ilan University , Ramat Gan , Israel
| | - Alon Harmelin
- f Department of Veterinary Resources , Weizmann Institute of Science , Rehovot , Israel
| | - Orit Pappo
- c Department of Pathology , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel
| | - Victoria Marcu-Malina
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel
| | - Ziv Ben-Ari
- b Liver Research Laboratory , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,d Sackler Faculty of Medicine , Tel Aviv University , Israel
| | - Ninette Amariglio
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,e The Mina and Everard Goodman Faculty of Life Sciences , Bar Ilan University , Ramat Gan , Israel
| | - Gideon Rechavi
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,d Sackler Faculty of Medicine , Tel Aviv University , Israel
| | - Itamar Goldstein
- a Sheba Cancer Research Center , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel.,d Sackler Faculty of Medicine , Tel Aviv University , Israel
| | - Michal Safran
- b Liver Research Laboratory , Chaim Sheba Academic Medical Center, Tel Hashomer , Israel
| |
Collapse
|
14
|
Zehavi L, Layani A, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R, Avni D. Abstract A15: MiR-377 targets E2F3 and alters the NF-κB signaling pathway through MAP3K7 in malignant melanoma. Cancer Res 2016. [DOI: 10.1158/1538-7445.nonrna15-a15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The incidence of cutaneous malignant melanoma continues to rise, and once the disease metastasizes it is almost inevitably fatal. We were the first to report that a large micro-RNA (miRNA) cluster on human chromosome 14q32, implicated in many types of cancers, is significantly down-regulated in melanoma, and have been studying this ‘tumor-suppressor miRNA cluster’ for several years now. MiR-377, one of the miRNAs located within this cluster, was studied in this work.
Methods: qRT-pCR was used to quantify miR-377 levels in melanoma cell lines and samples. Melanoma cell lines ectopically expressing miR-377 were generated by stable transfection and mRNA expression was assessed using mRNA arrays. Potential targets of miR-377 were identified through luciferase reporter assays. Cellular proliferation, migration and soft-agar colony formation were monitored in control and miR-377-expressing cells using cell biology techniques and protein expression was assessed by western blot.
Results: miR-377 is expressed in normal melanocytes but not in melanoma cell lines or samples. Its ectopic stable expression in melanoma cell lines decreased their proliferative and migratory capacity and their colony-forming capability. mRNA arrays of melanoma cells over-expressing miR-377 pointed to several down-regulated mRNAs that have putative binding sites for miR-377 in their 3'UTR, of which both E2F3 and MAP3K7 were found to be direct targets of miR-377.
E2F3, a potent transcriptional inducer of cell-cycle progression, was found to be elevated in melanoma cell lines, but decreased following ectopic expression of miR-377. Ectopic miR-377 also led to a decrease in the activity of a reporter plasmid containing three E2F DNA-binding sites linked to a luciferase cDNA sequence, demonstrating that miR-377 down-regulates E2F3-induced transcription.
MAP3K7, a serine/threonine kinase along the MAPK signaling pathway, was over-expressed in melanoma but decreased following ectopic expression of miR-377. MAP3K7 is known to be involved in the activation of NF-κB. MiR-377 over-expression led to decreased activity of a reporter plasmid containing two NF-κB DNA-binding sites and to decreased output along the NF-κB signaling pathway.
Conclusion Our results suggest that miR-377 is an important negative regulator of E2F and of the MAP3K7/NF-κB signaling pathway in melanoma cells. The NF-κB signaling has been implicated in the acquisition of resistance to B-Raf inhibition. It is tempting to speculate that silencing of miR-377 in melanoma promotes the tumorigenic and metastatic potential of the cells through activation of these pathways. Indeed we found in preliminary results that overexpression of miR-377 in melanoma cells resistance to PLX-4032 (Zelboraf), re-sensitized the cells to the drug.
Citation Format: Liron Zehavi, Adi Layani, Jasmine Jacob-Hirsch, Yechezkel Sidi, Raya Leibowitz-Amit, Dror Avni. MiR-377 targets E2F3 and alters the NF-κB signaling pathway through MAP3K7 in malignant melanoma. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr A15.
Collapse
Affiliation(s)
| | - Adi Layani
- Sheba Medical Center, Tel Hashomer, Israel
| | | | | | | | - Dror Avni
- Sheba Medical Center, Tel Hashomer, Israel
| |
Collapse
|
15
|
Pappa KI, Polyzos A, Jacob-Hirsch J, Amariglio N, Vlachos GD, Loutradis D, Anagnou NP. Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells. PLoS One 2015; 10:e0142229. [PMID: 26559525 PMCID: PMC4641642 DOI: 10.1371/journal.pone.0142229] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Accepted: 10/18/2015] [Indexed: 01/07/2023] Open
Abstract
Studies on individual types of gynecological cancers (GCs), utilizing novel expression technologies, have revealed specific pathogenetic patterns and gene markers for cervical (CC), endometrial (EC) and vulvar cancer (VC). Although the clinical phenotypes of the three types of gynecological cancers are discrete, the fact they originate from a common embryological origin, has led to the hypothesis that they might share common features reflecting regression to early embryogenesis. To address this question, we performed a comprehensive comparative analysis of their profiles. Our data identified both common features (pathways and networks) and novel distinct modules controlling the same deregulated biological processes in all three types. Specifically, four novel transcriptional modules were discovered regulating cell cycle and apoptosis. Integration and comparison of our data with other databases, led to the identification of common features among cancer types, embryonic stem (ES) cells and the newly discovered cell population of squamocolumnar (SC) junction of the cervix, considered to host the early cancer events. Conclusively, these data lead us to propose the presence of common features among gynecological cancers, other types of cancers, ES cells and the pre-malignant SC junction cells, where the novel E2F/NFY and MAX/CEBP modules play an important role for the pathogenesis of gynecological carcinomas.
Collapse
Affiliation(s)
- Kalliopi I. Pappa
- First Department of Obstetrics and Gynecology, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
- Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | - Alexander Polyzos
- Basic Research Centre, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | - Jasmine Jacob-Hirsch
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ninette Amariglio
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - George D. Vlachos
- First Department of Obstetrics and Gynecology, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
| | - Dimitrios Loutradis
- First Department of Obstetrics and Gynecology, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
| | - Nicholas P. Anagnou
- Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
- Laboratory of Biology, University of Athens School of Medicine, Athens, Greece
- * E-mail:
| |
Collapse
|
16
|
Zehavi L, Schayek H, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R, Avni D. MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma. Mol Cancer 2015; 14:68. [PMID: 25889255 PMCID: PMC4392476 DOI: 10.1186/s12943-015-0338-9] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Accepted: 03/10/2015] [Indexed: 11/21/2022] Open
Abstract
Background The incidence of cutaneous malignant melanoma continues to rise, and once the disease metastasizes it is almost inevitably fatal. We recently reported that a large miRNAs cluster on human chromosome 14q32, implicated in many types of cancers, is significantly down-regulated in melanoma. miR-377, one of the miRNAs located within this cluster, was studied here. Methods qRT-pCR was used to quantify miR-377 levels in melanoma cell lines and samples. Melanoma cell lines ectopically expressing miR-377 were generated by stable transfection, mRNA expression was assessed using mRNA arrays and protein expression was assessed by Western blot analysis. Potential targets of miR-377 were identified through luciferase reporter assays. Cellular proliferation, migration and soft-agar colony formation were monitored in control and miR-377-expressing cells using cell biology techniques. Results miR-377 is expressed in normal melanocytes but not in melanoma cell lines or samples. Its ectopic stable expression in melanoma cell lines decreased their proliferative and migratory capacity and their colony-forming capability. mRNA arrays of melanoma cells over-expressing miR-377 pointed to several down-regulated mRNAs that have putative binding sites for miR-377 in their 3′UTR, of which both E2F3 and MAP3K7 were found to be direct targets of miR-377. E2F3, a potent transcriptional inducer of cell-cycle progression, was found to be elevated in melanoma cell lines, but decreased following ectopic expression of miR-377. Ectopic miR-377 also led to a decrease in the activity of a reporter plasmid containing three E2F DNA-binding sites linked to a luciferase cDNA sequence, demonstrating that miR-377 down-regulates E2F3-induced transcription. MAP3K7 (known as TAK1), a serine/threonine kinase along the MAPK signaling pathway, was over-expressed in melanoma but decreased following ectopic expression of miR-377. MAP3K7 is involved in the activation of NF-κB. MiR-377 over-expression led to decreased activity of a reporter plasmid containing two NF-κB DNA-binding sites and to decreased output along the NF-kB signaling pathway. Conclusion Our results suggest that miR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells; it is tempting to speculate that its silencing in melanoma promotes the tumorigenic and metastatic potential of the cells through activation of these pathways. Electronic supplementary material The online version of this article (doi:10.1186/s12943-015-0338-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Liron Zehavi
- Center for Cancer Research Sheba Medical Center, Tel Hashomer, Israel. .,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | - Hagit Schayek
- Center for Cancer Research Sheba Medical Center, Tel Hashomer, Israel.
| | | | - Yechezkel Sidi
- Center for Cancer Research Sheba Medical Center, Tel Hashomer, Israel. .,Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, 52621, Israel. .,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | - Raya Leibowitz-Amit
- Center for Cancer Research Sheba Medical Center, Tel Hashomer, Israel. .,Institute of Oncology, Sheba Medical Center, Tel Hashomer, 52621, Israel.
| | - Dror Avni
- Center for Cancer Research Sheba Medical Center, Tel Hashomer, Israel. .,Laboratory of Molecular Cell Biology, Center for Cancer Research and Department of Medicine C, Sheba Medical Center, Tel Hashomer, 52621, Israel.
| |
Collapse
|
17
|
Edri R, Yaffe Y, Ziller MJ, Mutukula N, Volkman R, David E, Jacob-Hirsch J, Malcov H, Levy C, Rechavi G, Gat-Viks I, Meissner A, Elkabetz Y. Analysing human neural stem cell ontogeny by consecutive isolation of Notch active neural progenitors. Nat Commun 2015; 6:6500. [PMID: 25799239 PMCID: PMC4383005 DOI: 10.1038/ncomms7500] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 02/04/2015] [Indexed: 12/22/2022] Open
Abstract
Decoding heterogeneity of pluripotent stem cell (PSC)-derived neural progeny is fundamental for revealing the origin of diverse progenitors, for defining their lineages, and for identifying fate determinants driving transition through distinct potencies. Here we have prospectively isolated consecutively appearing PSC-derived primary progenitors based on their Notch activation state. We first isolate early neuroepithelial cells and show their broad Notch-dependent developmental and proliferative potential. Neuroepithelial cells further yield successive Notch-dependent functional primary progenitors, from early and midneurogenic radial glia and their derived basal progenitors, to gliogenic radial glia and adult-like neural progenitors, together recapitulating hallmarks of neural stem cell (NSC) ontogeny. Gene expression profiling reveals dynamic stage-specific transcriptional patterns that may link development of distinct progenitor identities through Notch activation. Our observations provide a platform for characterization and manipulation of distinct progenitor cell types amenable for developing streamlined neural lineage specification paradigms for modelling development in health and disease. Profiling pluripotent stem cell (PSC)-derived neural progeny is of fundamental interest for characterizing stem cell differentiation. Here, the authors analyse neural progenitors consecutively derived from human PSCs, showing dynamic stage-specific transcriptional patterns for distinct neural progenitors.
Collapse
Affiliation(s)
- Reuven Edri
- Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Yakey Yaffe
- Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Michael J Ziller
- 1] Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA [2] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - Naresh Mutukula
- Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Rotem Volkman
- Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Eyal David
- Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
| | - Jasmine Jacob-Hirsch
- 1] Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel [2] Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Hagar Malcov
- Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Carmit Levy
- Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Gideon Rechavi
- 1] Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel [2] Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Irit Gat-Viks
- Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
| | - Alexander Meissner
- 1] Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA [2] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - Yechiel Elkabetz
- Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| |
Collapse
|
18
|
Greenberg E, Hajdu S, Nemlich Y, Cohen R, Itzhaki O, Jacob-Hirsch J, Besser MJ, Schachter J, Markel G. Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biol 2015; 4:140030. [PMID: 24920276 PMCID: PMC4077061 DOI: 10.1098/rsob.140030] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The various roles of microRNAs (miRNAs) in controlling the phenotype of cancer cells are the focus of contemporary research efforts. We have recently shown that miR-17 directly targets the ADAR1 gene and thereby enhances melanoma cell aggressiveness. miR-17 and miR-20a belong to the miR-17/92 complex, and their mature forms are identical except for two non-seed nucleotides. Nevertheless, here we show that these two miRNAs carry markedly different effects on melanoma cells. A strong positive correlation was observed between the expression of miR-17 and miR-20a among various melanoma cultures. Luciferase assays showed that miR-17 but not miR-20a directly targets the 3’ untranslated region of the ADAR1 gene. Ectopic expression of these miRNAs in melanoma cells differentially alters the expression of five exemplar TargetScan-predicted target genes: ADAR1, ITGB8, TGFBR2, MMP2 and VEGF-A. Whole-genome expression microarrays confirm a markedly differential effect on the transcriptome. Functionally, over-expression of miR-20a but not of miR-17 in melanoma cells inhibits net proliferation in vitro. The differential functional effect was observed following ectopic expression of the mature miRNA or of the pre-miRNA sequences. This suggests that the two non-seed nucleotides dictate target sequence recognition and overall functional relevance. These miRNAs are clearly not redundant in melanoma cell biology.
Collapse
Affiliation(s)
- Eyal Greenberg
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Steven Hajdu
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel
| | - Yael Nemlich
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel
| | - Ronit Cohen
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Orit Itzhaki
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel
| | | | - Michal J Besser
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Jacob Schachter
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel
| | - Gal Markel
- Sheba Medical Center, Ella Institute of Melanoma, Ramat Gan, Israel Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel
| |
Collapse
|
19
|
Makovski V, Jacob-Hirsch J, Gefen-Dor C, Shai B, Ehrlich M, Rechavi G, Kloog Y. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway. Cell Death Dis 2014; 5:e1557. [PMID: 25476905 PMCID: PMC4649829 DOI: 10.1038/cddis.2014.502] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 10/07/2014] [Accepted: 10/13/2014] [Indexed: 12/14/2022]
Abstract
Mutations in tuberous sclerosis (TSC) genes cause the genetic disorder TSC, as well as other neoplasms, including lymphangioleiomyomatosis (LAM) and angiomyolipomas (AMLs). AMLs are benign renal tumors occur both in sporadic LAM and in TSC. As they carry the same mutations, AML cell lines serve as a model for TSC and LAM. Rheb/mammalian target of rapamycin complex 1 (mTORC1) pathway is chronically activated in TSC-deficient cells, and this activation can be diminished using the appropriate inhibitors. Rapamycin (sirolimus) is a known specific inhibitor of mTORC1, whereas S-trans,trans-farnesylthiosalicylic acid (FTS; salirasib) has been shown to inhibit Rheb. To examine the effect of the Rheb/mTOR inhibition pathway, we used human TSC2-deficient AML cells, derived from a LAM patient. FTS indeed inhibited Rheb in these cells and attenuated their proliferation. After comparative treatments with FTS or rapamycin or by re-expression of TSC2, we carried out a gene array analysis. This yielded a substantial number of commonly altered genes, many of which we identified as downstream targets of the interferon (IFN) regulatory factor 7 (IRF7) transcription factor, a central activator of the IFN type 1 immune response. Furthermore, nuclear localization of IRF7 was impaired by each of the three treatments. Interestingly, the phenomena seen on FTS or rapamycin treatment were selective for TSC2-deficient cells. Moreover, knockdown of IRF7 by siRNA mimicked the decrease in number of the abovementioned genes and also inhibited AML cell proliferation. Altogether, these findings support FTS as a potential treatment for TSC and its related pathologies and IRF7 as a novel target for treatment.
Collapse
Affiliation(s)
- V Makovski
- Department of Neurobiology, The George S Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel
| | - J Jacob-Hirsch
- Department of Pediatric Hematology-Oncology, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel
| | - C Gefen-Dor
- Department of Pediatric Hematology-Oncology, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel
| | - B Shai
- Department of Cell Research and Immunology, The George S Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel
| | - M Ehrlich
- Department of Cell Research and Immunology, The George S Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel
| | - G Rechavi
- 1] Department of Pediatric Hematology-Oncology, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel [2] Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Y Kloog
- Department of Neurobiology, The George S Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel
| |
Collapse
|
20
|
Plaks V, Gershon E, Zeisel A, Jacob-Hirsch J, Neeman M, Winterhager E, Rechavi G, Domany E, Dekel N. Blastocyst implantation failure relates to impaired translational machinery gene expression. Reproduction 2014; 148:87-98. [PMID: 24700326 DOI: 10.1530/rep-13-0395] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Oocyte quality is a well-established determinant of embryonic fate. However, the molecular participants and biological markers that affect and may predict adequate embryonic development are largely elusive. Our aim was to identify the components of the oocyte molecular machinery that part take in the production of a healthy embryo. For this purpose, we used an animal model, generated by us previously, the oocytes of which do not express Cx43 (Cx43(del/del)). In these mice, oogenesis appears normal, fertilisation does occur, early embryonic development is successful but implantation fails. We used magnetic resonance imaging analysis combined with histological examination to characterise the embryonic developmental incompetence. Reciprocal embryo transfer confirmed that the blastocyst evolved from the Cx43(del/del) oocyte is responsible for the implantation disorder. In order to unveil the genes, the impaired expression of which brings about the development of defective embryos, we carried out a genomic screening of both the oocytes and the resulting blastocysts. This microarray analysis revealed a low expression of Egr1, Rpl21 and Eif4a1 in Cx43(del/del) oocytes and downregulation of Rpl15 and Eif4g2 in the resulting blastocysts. We propose that global deficiencies in genes related to the expression of ribosomal proteins and translation initiation factors in apparently normal oocytes bring about accumulation of defects, which significantly compromise their developmental capacity. The blastocysts resulting from such oocytes, which grow within a confined space until implantation, may be unable to generate enough biological mass to allow their expansion. This information could be implicated to diagnosis and treatment of infertility, particularly to IVF.
Collapse
Affiliation(s)
- Vicki Plaks
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Eran Gershon
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Amit Zeisel
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Jasmine Jacob-Hirsch
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Michal Neeman
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Elke Winterhager
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Gideon Rechavi
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Eytan Domany
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| | - Nava Dekel
- Departments of Biological RegulationPhysics of Complex SystemsThe Weizmann Institute of Science, Rehovot 76100, IsraelInstitute of AnatomyUniversity Hospital Duisburg-Essen, Essen, GermanyThe Sheba Cancer Research CenterSheba Medical Center, Tel Hashomer, Israel
| |
Collapse
|
21
|
Ben-Shoshan SO, Simon AJ, Jacob-Hirsch J, Shaklai S, Paz-Yaacov N, Amariglio N, Rechavi G, Trakhtenbrot L. Induction of polyploidy by nuclear fusion mechanism upon decreased expression of the nuclear envelope protein LAP2β in the human osteosarcoma cell line U2OS. Mol Cytogenet 2014; 7:9. [PMID: 24472424 PMCID: PMC3926685 DOI: 10.1186/1755-8166-7-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Accepted: 01/10/2014] [Indexed: 01/15/2023] Open
Abstract
Background Polyploidy has been recognized for many years as an important hallmark of cancer cells. Polyploid cells can arise through cell fusion, endoreplication and abortive cell cycle. The inner nuclear membrane protein LAP2β plays key roles in nuclear envelope breakdown and reassembly during mitosis, initiation of replication and transcriptional repression. Here we studied the function of LAP2β in the maintenance of cell ploidy state, a role which has not yet been assigned to this protein. Results By knocking down the expression of LAP2β, using both viral and non-viral RNAi approaches in osteosarcoma derived U2OS cells, we detected enlarged nuclear size, nearly doubling of DNA content and chromosomal duplications, as analyzed by fluorescent in situ hybridization and spectral karyotyping methodologies. Spectral karyotyping analyses revealed that near-hexaploid karyotypes of LAP2β knocked down cells consisted of not only seven duplicated chromosomal markers, as could be anticipated by genome duplication mechanism, but also of four single chromosomal markers. Furthermore, spectral karyotyping analysis revealed that both of two near-triploid U2OS sub-clones contained the seven markers that were duplicated in LAP2β knocked down cells, whereas the four single chromosomal markers were detected only in one of them. Gene expression profiling of LAP2β knocked down cells revealed that up to a third of the genes exhibiting significant changes in their expression are involved in cancer progression. Conclusions Our results suggest that nuclear fusion mechanism underlies the polyploidization induction upon LAP2β reduced expression. Our study implies on a novel role of LAP2β in the maintenance of cell ploidy status. LAP2β depleted U2OS cells can serve as a model to investigate polyploidy and aneuploidy formation by nuclear fusion mechanism and its involvement in cancerogenesis.
Collapse
Affiliation(s)
- Shirley Oren Ben-Shoshan
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Amos J Simon
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.,Institute of Hematology, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel
| | - Jasmine Jacob-Hirsch
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel
| | - Sigal Shaklai
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel
| | - Nurit Paz-Yaacov
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel
| | - Ninette Amariglio
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.,Institute of Hematology, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel
| | - Gideon Rechavi
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Luba Trakhtenbrot
- Sheba Cancer Research Center, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.,Institute of Hematology, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel
| |
Collapse
|
22
|
Bazak L, Haviv A, Barak M, Jacob-Hirsch J, Deng P, Zhang R, Isaacs FJ, Rechavi G, Li JB, Eisenberg E, Levanon EY. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res 2013; 24:365-76. [PMID: 24347612 PMCID: PMC3941102 DOI: 10.1101/gr.164749.113] [Citation(s) in RCA: 410] [Impact Index Per Article: 37.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
RNA molecules transmit the information encoded in the genome and generally reflect its content. Adenosine-to-inosine (A-to-I) RNA editing by ADAR proteins converts a genomically encoded adenosine into inosine. It is known that most RNA editing in human takes place in the primate-specific Alu sequences, but the extent of this phenomenon and its effect on transcriptome diversity are not yet clear. Here, we analyzed large-scale RNA-seq data and detected ∼1.6 million editing sites. As detection sensitivity increases with sequencing coverage, we performed ultradeep sequencing of selected Alu sequences and showed that the scope of editing is much larger than anticipated. We found that virtually all adenosines within Alu repeats that form double-stranded RNA undergo A-to-I editing, although most sites exhibit editing at only low levels (<1%). Moreover, using high coverage sequencing, we observed editing of transcripts resulting from residual antisense expression, doubling the number of edited sites in the human genome. Based on bioinformatic analyses and deep targeted sequencing, we estimate that there are over 100 million human Alu RNA editing sites, located in the majority of human genes. These findings set the stage for exploring how this primate-specific massive diversification of the transcriptome is utilized.
Collapse
Affiliation(s)
- Lily Bazak
- Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 52900, Israel
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Bahar-Shany K, Brand H, Sapoznik S, Jacob-Hirsch J, Yung Y, Korach J, Perri T, Cohen Y, Hourvitz A, Levanon K. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol 2013; 132:322-7. [PMID: 24355484 DOI: 10.1016/j.ygyno.2013.12.015] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Revised: 12/01/2013] [Accepted: 12/06/2013] [Indexed: 10/25/2022]
Abstract
OBJECTIVES Ovulation-related inflammation is suspected to have a causal role in ovarian carcinogenesis, but there are no human models to study the molecular pathways. Our aim is to develop such an ex-vivo model based on human fallopian tube (FT) epithelium exposed to human follicular fluid (FF). METHODS FT epithelium was dissociated from normal surgical specimens. FF was obtained from donors undergoing in-vitro fertilization. The cells were cultured on collagen-coated Transwells and incubated with FF for various periods of time. The transcriptomic changes resulting from FF treatment were profiled using Affymetrix expression arrays. Specific characteristics of the FT pre-cancerous lesions were studied using immunohistochemistry, immunofluorescence, RT-PCR and XTT assay. RESULTS We show that FF exposure causes up-regulation of inflammatory and DNA repair pathways. Double stranded DNA breaks are induced. There is a minor increase in cell proliferation. TP53, which is the hallmark of the precursor lesion in-vivo, is accumulated. Levels of expression and secretion of Interleukin-8 are significantly increased. CONCLUSIONS Our model addresses the main non-genetic risk factor for ovarian cancer, namely the impact of ovulation. This study demonstrates the biological implications of in-vitro exposure of human FT epithelial cells to FF. The model replicates elements characterizing the precursor lesions of ovarian cancer, and warrants further investigation of the linkage between repeated exposure to ovulation-related damage and accumulation of neoplastic changes.
Collapse
Affiliation(s)
- K Bahar-Shany
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
| | - H Brand
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel
| | - S Sapoznik
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
| | - J Jacob-Hirsch
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
| | - Y Yung
- IVF Unit and Reproduction Lab, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat-Gan 52621, Israel
| | - J Korach
- Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
| | - T Perri
- Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
| | - Y Cohen
- Institutional Tumor Banks, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
| | - A Hourvitz
- Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel; IVF Unit and Reproduction Lab, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat-Gan 52621, Israel
| | - K Levanon
- Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel; The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2012, Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan 52621, Israel.
| |
Collapse
|
24
|
Germanguz I, Shtrichman R, Osenberg S, Ziskind A, Novak A, Domev H, Laevsky I, Jacob-Hirsch J, Feiler Y, Rechavi G, Itskovitz-Eldor J. ADAR1 is involved in the regulation of reprogramming human fibroblasts to induced pluripotent stem cells. Stem Cells Dev 2013; 23:443-56. [PMID: 24192045 DOI: 10.1089/scd.2013.0206] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Adenosine-to-inosine (A-to-I) RNA editing is a post-transcriptional, site-specific modification process that is catalyzed by Adenosine Deaminase Acting on RNA (ADAR) gene family members. Since ADARs act on double-stranded RNA, most A-to-I editing occurs within repetitive elements, particularly Alu elements, as the result of the inherent property of these sequences to fold and form double strands. ADAR1-mediated A-to-I RNA editing was recently implicated in the regulation of human embryonic stem cells (hESCs). Spontaneous and neuronal differentiation of hESC was shown to result in a decrease in A-to-I editing levels. Knockdown of ADAR1 in hESCs results in an elevation of the expression of differentiation-related genes. In addition, we found that hESCs over-expressing ADAR1 could not be generated. The current study shows that the editing levels of induced pluripotent stem cells (iPSCs) change throughout reprogramming, from a source cell level to a level similar to that of hESCs. Up- or down-regulation of the ADAR1 level in human foreskin fibroblast (HFF) cells before induction of reprogramming results in varied reprogramming efficiencies. Furthermore, HFF-iPSC early clones derived from source cells in which the ADAR1 level was down-regulated lose their iPSC properties shortly after iPSC colony formation and instead exhibit characteristics of cancer cells. Taken together, our results imply a role for ADAR1 in the regulation of pluripotency induction as well as in the maintenance of early iPSC properties.
Collapse
Affiliation(s)
- Igal Germanguz
- 1 Ruth and Bruce Rappaport Faculty of Medicine, Sohnis and Forman Families Center for Stem Cell and Tissue Regeneration Research , Technion, Haifa, Israel
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Köstler WJ, Zeisel A, Körner C, Tsai JM, Jacob-Hirsch J, Ben-Chetrit N, Sharma K, Cohen-Dvashi H, Yitzhaky A, Lader E, Tschulena U, Rechavi G, Domany E, Wiemann S, Yarden Y. Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration. PLoS One 2013; 8:e80566. [PMID: 24324612 PMCID: PMC3855657 DOI: 10.1371/journal.pone.0080566] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2013] [Accepted: 10/03/2013] [Indexed: 11/28/2022] Open
Abstract
Signal-induced transcript isoform variation (TIV) includes alternative promoter usage as well as alternative splicing and alternative polyadenylation of mRNA. To assess the phenotypic relevance of signal-induced TIV, we employed exon arrays and breast epithelial cells, which migrate in response to the epidermal growth factor (EGF). We show that EGF rapidly – within one hour – induces widespread TIV in a significant fraction of the transcriptome. Importantly, TIV characterizes many genes that display no differential expression upon stimulus. In addition, similar EGF-dependent changes are shared by a panel of mammary cell lines. A functional screen, which utilized isoform-specific siRNA oligonucleotides, indicated that several isoforms play essential, non-redundant roles in EGF-induced mammary cell migration. Taken together, our findings highlight the importance of TIV in the rapid evolvement of a phenotypic response to extracellular signals.
Collapse
Affiliation(s)
- Wolfgang J. Köstler
- Departments of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - Amit Zeisel
- Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
| | - Cindy Körner
- Division of Molecular Genome Analysis, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Jonathan M. Tsai
- Departments of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - Jasmine Jacob-Hirsch
- Sheba Cancer Research Center, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Nir Ben-Chetrit
- Departments of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - Kirti Sharma
- Division of Molecular Genome Analysis, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Hadas Cohen-Dvashi
- Departments of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - Assif Yitzhaky
- Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
| | - Eric Lader
- Qiagen, Frederick, Maryland, United States of America
| | - Ulrich Tschulena
- Division of Molecular Genome Analysis, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Gideon Rechavi
- Sheba Cancer Research Center, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Eytan Domany
- Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
- * E-mail: (YY); (ED)
| | - Stefan Wiemann
- Division of Molecular Genome Analysis, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Yosef Yarden
- Departments of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
- * E-mail: (YY); (ED)
| |
Collapse
|
26
|
Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest 2013; 123:2703-18. [PMID: 23728176 DOI: 10.1172/jci62980] [Citation(s) in RCA: 139] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2012] [Accepted: 03/21/2013] [Indexed: 12/15/2022] Open
Abstract
Some solid tumors have reduced posttranscriptional RNA editing by adenosine deaminase acting on RNA (ADAR) enzymes, but the functional significance of this alteration has been unclear. Here, we found the primary RNA-editing enzyme ADAR1 is frequently reduced in metastatic melanomas. In situ analysis of melanoma samples using progression tissue microarrays indicated a substantial downregulation of ADAR1 during the metastatic transition. Further, ADAR1 knockdown altered cell morphology, promoted in vitro proliferation, and markedly enhanced the tumorigenicity in vivo. A comparative whole genome expression microarray analysis revealed that ADAR1 controls the expression of more than 100 microRNAs (miRNAs) that regulate many genes associated with the observed phenotypes. Importantly, we discovered that ADAR1 fundamentally regulates miRNA processing in an RNA binding–dependent, yet RNA editing–independent manner by regulating Dicer expression at the translational level via let-7. In addition, ADAR1 formed a complex with DGCR8 that was mutually exclusive with the DGCR8-Drosha complex that processes pri-miRNAs in the nucleus. We found that cancer cells silence ADAR1 by overexpressing miR-17 and miR-432, which both directly target the ADAR1 transcript. We further demonstrated that the genes encoding miR-17 and miR-432 are frequently amplified in melanoma and that aberrant hypomethylation of the imprinted DLK1-DIO3 region in chromosome 14 can also drive miR-432 overexpression.
Collapse
|
27
|
Burko Y, Shleizer-Burko S, Yanai O, Shwartz I, Zelnik ID, Jacob-Hirsch J, Kela I, Eshed-Williams L, Ori N. A role for APETALA1/fruitfull transcription factors in tomato leaf development. Plant Cell 2013; 25:2070-83. [PMID: 23771895 PMCID: PMC3723613 DOI: 10.1105/tpc.113.113035] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Flexible maturation rates underlie part of the diversity of leaf shape, and tomato (Solanum lycopersicum) leaves are compound due to prolonged organogenic activity of the leaf margin. The CINCINNATA-teosinte branched1, cycloidea, PCF (CIN-TCP) transcription factor lanceolate (LA) restricts this organogenic activity and promotes maturation. Here, we show that tomato APETALA1/fruitfull (AP1/FUL) MADS box genes are involved in tomato leaf development and are repressed by LA. AP1/FUL expression is correlated negatively with LA activity and positively with the organogenic activity of the leaf margin. LA binds to the promoters of the AP1/FUL genes MBP20 and TM4. Overexpression of MBP20 suppressed the simple-leaf phenotype resulting from upregulation of LA activity or from downregulation of class I knotted like homeobox (KNOXI) activity. Overexpression of a dominant-negative form of MBP20 led to leaf simplification and partly suppressed the increased leaf complexity of plants with reduced LA activity or increased KNOXI activity. Tomato plants overexpressing miR319, a negative regulator of several CIN-TCP genes including LA, flower with fewer leaves via an SFT-dependent pathway, suggesting that miR319-sensitive CIN-TCPs delay flowering in tomato. These results identify a role for AP1/FUL genes in vegetative development and show that leaf and plant maturation are regulated via partially independent mechanisms.
Collapse
Affiliation(s)
- Yogev Burko
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
| | - Sharona Shleizer-Burko
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
| | - Osnat Yanai
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
| | - Ido Shwartz
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
| | - Iris Daphne Zelnik
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
| | - Jasmine Jacob-Hirsch
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
| | - Itai Kela
- Physics of Complex Systems, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Leor Eshed-Williams
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
| | - Naomi Ori
- The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture and The Otto Warburg Minerva Center for Agricultural Biotechnology, Hebrew University, Rehovot 76100, Israel
- Address correspondence to
| |
Collapse
|
28
|
Moyal L, Barzilai A, Gorovitz B, Hirshberg A, Amariglio N, Jacob-Hirsch J, Maron L, Feinmesser M, Hodak E. miR-155 is involved in tumor progression of mycosis fungoides. Exp Dermatol 2013; 22:431-3. [DOI: 10.1111/exd.12161] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2013] [Indexed: 12/23/2022]
|
29
|
Solomon O, Oren S, Safran M, Deshet-Unger N, Akiva P, Jacob-Hirsch J, Cesarkas K, Kabesa R, Amariglio N, Unger R, Rechavi G, Eyal E. Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR). RNA 2013; 19:591-604. [PMID: 23474544 PMCID: PMC3677275 DOI: 10.1261/rna.038042.112] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Alternative mRNA splicing is a major mechanism for gene regulation and transcriptome diversity. Despite the extent of the phenomenon, the regulation and specificity of the splicing machinery are only partially understood. Adenosine-to-inosine (A-to-I) RNA editing of pre-mRNA by ADAR enzymes has been linked to splicing regulation in several cases. Here we used bioinformatics approaches, RNA-seq and exon-specific microarray of ADAR knockdown cells to globally examine how ADAR and its A-to-I RNA editing activity influence alternative mRNA splicing. Although A-to-I RNA editing only rarely targets canonical splicing acceptor, donor, and branch sites, it was found to affect splicing regulatory elements (SREs) within exons. Cassette exons were found to be significantly enriched with A-to-I RNA editing sites compared with constitutive exons. RNA-seq and exon-specific microarray revealed that ADAR knockdown in hepatocarcinoma and myelogenous leukemia cell lines leads to global changes in gene expression, with hundreds of genes changing their splicing patterns in both cell lines. This global change in splicing pattern cannot be explained by putative editing sites alone. Genes showing significant changes in their splicing pattern are frequently involved in RNA processing and splicing activity. Analysis of recently published RNA-seq data from glioblastoma cell lines showed similar results. Our global analysis reveals that ADAR plays a major role in splicing regulation. Although direct editing of the splicing motifs does occur, we suggest it is not likely to be the primary mechanism for ADAR-mediated regulation of alternative splicing. Rather, this regulation is achieved by modulating trans-acting factors involved in the splicing machinery.
Collapse
Affiliation(s)
- Oz Solomon
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
- The Everard & Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 52900, Israel
| | - Shirley Oren
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Michal Safran
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
| | - Naamit Deshet-Unger
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
| | - Pinchas Akiva
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Jasmine Jacob-Hirsch
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
| | - Karen Cesarkas
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
| | - Reut Kabesa
- The Everard & Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 52900, Israel
| | - Ninette Amariglio
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
| | - Ron Unger
- The Everard & Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 52900, Israel
| | - Gideon Rechavi
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
| | - Eran Eyal
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
- Corresponding authorE-mail
| |
Collapse
|
30
|
Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling. Cancer Prev Res (Phila) 2013; 6:82-90. [PMID: 23341570 DOI: 10.1158/1940-6207.capr-12-0105] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Approximately 5% of all breast cancers can be attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2. We searched for genes that have the potential to distinguish healthy BRCA1 and BRCA2 mutation carriers from noncarriers based on differences in expression profiling. Using expression microarrays, we compared gene expression of irradiated lymphocytes from BRCA1 and BRCA2 mutation carriers versus control noncarriers. We identified 137 probe sets in BRCA1 carriers and 1,345 in BRCA2 carriers with differential gene expression. Gene Ontology analysis revealed that most of these genes relate to regulation pathways of DNA repair processes, cell-cycle regulation, and apoptosis. Real-time PCR was conducted on the 36 genes, which were most prominently differentially expressed in the microarray assay; 21 genes were shown to be significantly differentially expressed in BRCA1 and/or BRCA2 mutation carriers as compared with controls (P < 0.05). On the basis of a validation study with 40 mutation carriers and 17 noncarriers, a multiplex model that included six or more coincidental genes of 18 selected genes was constructed to predict the risk of carrying a mutation. The results using this model showed sensitivity 95% and specificity 88%. In summary, our study provides insight into the biologic effect of heterozygous mutations in BRCA1 and BRCA2 genes in response to ionizing irradiation-induced DNA damage. We also suggest a set of 18 genes that can serve as a prediction and screening tool for BRCA1 or BRCA2 mutational carriers by using easily obtained lymphocytes.
Collapse
Affiliation(s)
- Asher Y Salmon
- Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
| | | | | | | | | | | | | |
Collapse
|
31
|
Tovin A, Alon S, Ben-Moshe Z, Mracek P, Vatine G, Foulkes NS, Jacob-Hirsch J, Rechavi G, Toyama R, Coon SL, Klein DC, Eisenberg E, Gothilf Y. Systematic identification of rhythmic genes reveals camk1gb as a new element in the circadian clockwork. PLoS Genet 2012; 8:e1003116. [PMID: 23284293 PMCID: PMC3527293 DOI: 10.1371/journal.pgen.1003116] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Accepted: 10/11/2012] [Indexed: 11/18/2022] Open
Abstract
A wide variety of biochemical, physiological, and molecular processes are known to have daily rhythms driven by an endogenous circadian clock. While extensive research has greatly improved our understanding of the molecular mechanisms that constitute the circadian clock, the links between this clock and dependent processes have remained elusive. To address this gap in our knowledge, we have used RNA sequencing (RNA–seq) and DNA microarrays to systematically identify clock-controlled genes in the zebrafish pineal gland. In addition to a comprehensive view of the expression pattern of known clock components within this master clock tissue, this approach has revealed novel potential elements of the circadian timing system. We have implicated one rhythmically expressed gene, camk1gb, in connecting the clock with downstream physiology of the pineal gland. Remarkably, knockdown of camk1gb disrupts locomotor activity in the whole larva, even though it is predominantly expressed within the pineal gland. Therefore, it appears that camk1gb plays a role in linking the pineal master clock with the periphery. The circadian clock is a molecular pacemaker that drives rhythmic expression of genes with a ∼24-hour period. As a result, many physiological processes have daily rhythms. Many of the conserved elements that constitute the circadian clock are known, but the links between the clock and dependent processes have remained elusive. With its amenability to genetic manipulations and a variety of genetic tools, the zebrafish has become an attractive vertebrate model for the quest to identify and characterize novel clock components. Here, we take advantage of another attraction of the zebrafish, the fact that its pineal gland is the site of a central clock which directly receives light input and autonomously generates circadian rhythms that affect the physiology of the whole organism. We show that the systematic design and analysis of genome-wide experiments based on the zebrafish pineal gland can lead to the discovery of new clock elements. We have characterized one novel element, camk1gb, and show that this gene, predominantly expressed within the pineal gland and driven by the circadian clock, links circadian clock timing with locomotor activity in zebrafish larvae.
Collapse
Affiliation(s)
- Adi Tovin
- Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Shahar Alon
- Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
| | - Zohar Ben-Moshe
- Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Philipp Mracek
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein, Germany
| | - Gad Vatine
- Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Nicholas S. Foulkes
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein, Germany
| | - Jasmine Jacob-Hirsch
- Cancer Research Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gideon Rechavi
- Cancer Research Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Reiko Toyama
- Laboratory of Molecular Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Steven L. Coon
- Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
| | - David C. Klein
- Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Eli Eisenberg
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Raymond and Beverly Sackler School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
- * E-mail: (YG); (EE)
| | - Yoav Gothilf
- Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- * E-mail: (YG); (EE)
| |
Collapse
|
32
|
Eyal E, Tohami T, Amir A, Cesarkas K, Jacob-Hirsch J, Volchek Y, Nagler A, Rechavi G, Amariglio N. Detection ofBCR-ABL1mutations in chronic myeloid leukaemia by massive parallel sequencing. Br J Haematol 2012; 160:477-86. [DOI: 10.1111/bjh.12171] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Accepted: 10/29/2012] [Indexed: 11/29/2022]
Affiliation(s)
- Eran Eyal
- Cancer Research Centre; Chaim Sheba Medical Centre; Tel-Hashomer; Israel
| | - Tali Tohami
- Division of Haematology; Chaim Sheba Medical Centre; Tel-Hashomer; Israel
| | - Amnon Amir
- Cancer Research Centre; Chaim Sheba Medical Centre; Tel-Hashomer; Israel
| | - Karen Cesarkas
- Cancer Research Centre; Chaim Sheba Medical Centre; Tel-Hashomer; Israel
| | | | - Yuliya Volchek
- Division of Haematology; Chaim Sheba Medical Centre; Tel-Hashomer; Israel
| | | | | | - Ninette Amariglio
- Division of Haematology; Chaim Sheba Medical Centre; Tel-Hashomer; Israel
| |
Collapse
|
33
|
Nevo Y, Kamhi E, Jacob-Hirsch J, Amariglio N, Rechavi G, Sperling J, Sperling R. Genome-wide activation of latent donor splice sites in stress and disease. Nucleic Acids Res 2012; 40:10980-94. [PMID: 23002147 PMCID: PMC3510495 DOI: 10.1093/nar/gks834] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Sequences that conform to the 5′ splice site (5′SS) consensus are highly abundant in mammalian introns. Most of these sequences are preceded by at least one in-frame stop codon; thus, their use for splicing would result in pre-maturely terminated aberrant mRNAs. In normally grown cells, such intronic 5′SSs appear not to be selected for splicing. However, under heat shock conditions aberrant splicing involving such latent 5′SSs occurred in a number of specific gene transcripts. Using a splicing-sensitive microarray, we show here that stress-induced (e.g. heat shock) activation of latent splicing is widespread across the human transcriptome, thus highlighting the possibility that latent splicing may underlie certain diseases. Consistent with this notion, our analyses of data from the Gene Expression Omnibus (GEO) revealed widespread activation of latent splicing in cells grown under hypoxia and in certain cancers such as breast cancer and gliomas. These changes were found in thousands of transcripts representing a wide variety of functional groups; among them are genes involved in cell proliferation and differentiation. The GEO analysis also revealed a set of gene transcripts in oligodendroglioma, in which the level of activation of latent splicing increased with the severity of the disease.
Collapse
Affiliation(s)
- Yuval Nevo
- Department of Genetics, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | | | | | | | | | | | | |
Collapse
|
34
|
Guttman-Yassky E, Chiricozzi A, Jacob-Hirsch J, Tintle S, Khatcherian A, Amariglio N, Rechavi G, Krueger J, Nisticò S, Bergman R, Sarid R. Gene Expression Profiling Associated with the Progression of Classic Kaposi's Sarcoma. EUR J INFLAMM 2012. [DOI: 10.1177/1721727x1201000313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Although Kaposi's sarcoma (KS) gene expression profile is closer to lymphatic (LEC) rather than blood vascular endothelial cells (BEC), uncertainty still surrounds the cellular origin of KS. To follow KS progression from early to late (nodular) stage, and characterize the molecular fingerprinting associated with each stage, gene arrays were used to compare gene expression profile of 9 skin samples of classic KS (4 Early, 2 Mixed, and 3 Nodular CKS samples) to 4 normal samples. Results for selected genes were validated by Real-time (RT) PCR and immunohistochemistry. Genes regulating immune and defense responses, angiogenesis, apoptosis and proliferation were differentially expressed in different KS stages compared to normal skin. Hierarchical clustering separated normal skin from KS with a clear gradient from early to nodular KS lesions. The gene expression level of endothelium markers, metalloproteinases, angiogenic factors and chemokines, gradually increased from normal through all KS stages. The expression of LEC genes highly increased from early to nodular KS. In the initiation phase we noticed a higher expression of growth factors, as compared to progressive stages. LEC and BEC markers co-exist in “KS expression signature”, although the LEC signature prevailed. Our results also show a complex environment of inflammatory cells and chemokines during KS evolution. A pathogenic hypothesis where cellular hyperproliferation is driven by local expression of chemokines and growth factors without clonal expansion of cells is suggested.
Collapse
Affiliation(s)
- E. Guttman-Yassky
- Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- Department of Dermatology, Weill-Cornell Medical College, Cornell University, New York, USA
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
| | - A. Chiricozzi
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
- Department of Dermatology, University of Rome Tor Vergata
| | - J. Jacob-Hirsch
- Institute of Hematology and Sheba Cancer Research Center Tel Hashomer Sackler School of Medicine, Tel Aviv University, Israel
| | - S. Tintle
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
| | - A. Khatcherian
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
| | - N. Amariglio
- Institute of Hematology and Sheba Cancer Research Center Tel Hashomer Sackler School of Medicine, Tel Aviv University, Israel
| | - G. Rechavi
- Institute of Hematology and Sheba Cancer Research Center Tel Hashomer Sackler School of Medicine, Tel Aviv University, Israel
| | - J.G. Krueger
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
| | - S.P. Nisticò
- Department of Dermatology, University of Rome Tor Vergata
| | - R. Bergman
- Department of Dermatology, Rambam Medical Center and the Technion, Haifa, Israel
| | - R. Sarid
- Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| |
Collapse
|
35
|
Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene 2012; 31:3569-83. [PMID: 22139081 PMCID: PMC3616212 DOI: 10.1038/onc.2011.547] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Revised: 09/25/2011] [Accepted: 10/18/2011] [Indexed: 12/30/2022]
Abstract
The HER2/neu oncogene encodes a receptor-like tyrosine kinase whose overexpression in breast cancer predicts poor prognosis and resistance to conventional therapies. However, the mechanisms underlying aggressiveness of HER2 (human epidermal growth factor receptor 2)-overexpressing tumors remain incompletely understood. Because it assists epidermal growth factor (EGF) and neuregulin receptors, we overexpressed HER2 in MCF10A mammary cells and applied growth factors. HER2-overexpressing cells grown in extracellular matrix formed filled spheroids, which protruded outgrowths upon growth factor stimulation. Our transcriptome analyses imply a two-hit model for invasive growth: HER2-induced proliferation and evasion from anoikis generate filled structures, which are morphologically and transcriptionally analogous to preinvasive patients' lesions. In the second hit, EGF escalates signaling and transcriptional responses leading to invasive growth. Consistent with clinical relevance, a gene expression signature based on the HER2/EGF-activated transcriptional program can predict poorer prognosis of a subgroup of HER2-overexpressing patients. In conclusion, the integration of a three-dimensional cellular model and clinical data attributes progression of HER2-overexpressing lesions to EGF-like growth factors acting in the context of the tumor's microenvironment.
Collapse
MESH Headings
- Anoikis/physiology
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/pathology
- Cell Line, Tumor
- Cell Proliferation
- Cell Transformation, Neoplastic/pathology
- Extracellular Matrix/physiology
- Female
- Gene Expression Profiling
- Humans
- Intercellular Signaling Peptides and Proteins/physiology
- Mammary Glands, Human/metabolism
- Mammary Glands, Human/pathology
- Models, Biological
- Neoplasm Invasiveness
- Precancerous Conditions/pathology
- Receptor, ErbB-2/physiology
- Spheroids, Cellular/physiology
- Transcription, Genetic/physiology
Collapse
Affiliation(s)
- C-R Pradeep
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - A Zeisel
- Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
| | - WJ Köstler
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - M Lauriola
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - J Jacob-Hirsch
- Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - B Haibe-Kains
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
- Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium
| | - N Amariglio
- Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - N Ben-Chetrit
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - A Emde
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - I Solomonov
- Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel
| | - G Neufeld
- Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
| | - M Piccart
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
| | - I Sagi
- Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel
| | - C Sotiriou
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
| | - G Rechavi
- Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Domany
- Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
| | - C Desmedt
- Institut Jules Bordet, Translational Research Unit, Brussels, Belgium
| | - Y Yarden
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| |
Collapse
|
36
|
Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, D'Orazi G. Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget 2012; 2:1191-202. [PMID: 22202117 PMCID: PMC3282077 DOI: 10.18632/oncotarget.395] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Hypoxia-inducible factor 1 (HIF-1), the major transcription factor specifically activated during hypoxia, regulates genes involved in critical aspects of cancer biology, including angiogenesis, cell proliferation, glycolysis and invasion. The HIF-1a subunit is stabilized by low oxygen, genetic alteration and cobaltous ions, and its over-expression correlates with drug resistance and increased cancer mortality in various cancer types, therefore representing an important anticancer target. Zinc supplementation has been shown to counteract the hypoxic phenotype in cancer cells, in vitro and in vivo, hence, understanding the molecular pathways modulated by zinc under hypoxia may provide the basis for reprogramming signalling pathways for anticancer therapy. Here we performed genome-wide analyses of colon cancer cells treated with combinations of cobalt, zinc and anticancer drug and evaluated the effect of zinc on gene expression patterns. Using Principal Component Analysis we found that zinc markedly reverted the cobalt-induced changes of gene expression, with reactivation of the drug-induced transcription of pro-apoptotic genes. We conclude that the hypoxia pathway is a potential therapeutic target addressed by zinc that also influences tumor cell response to anticancer drug.
Collapse
Affiliation(s)
- Michal Sheffer
- Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot 76100, Israel
| | | | | | | | | | | | | |
Collapse
|
37
|
Schayek H, Bentov I, Jacob-Hirsch J, Yeung C, Khanna C, Helman LJ, Plymate SR, Werner H. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. Horm Metab Res 2012; 44:511-9. [PMID: 22495974 DOI: 10.1055/s-0032-1311566] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The insulin-like growth factor-I (IGF-IR) and androgen (AR) receptors are important players in prostate cancer. Functional interactions between the IGF-I and androgen signaling pathways have crucial roles in the progression of prostate cancer from early to advanced stages. DNA methylation is a major epigenetic alteration affecting gene expression. Hypermethylation of tumor suppressor promoters is a frequent event in human cancer, leading to inactivation and repression of specific genes. The aim of the present study was to identify the entire set of methylated genes ("methylome") in a cellular model that replicates prostate cancer progression. The methylation profiles of the P69 (early stage, benign) and M12 (advanced stage, metastatic) prostate cancer cell lines were established by treating cells with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza) followed by DNA microarray analysis. Comparative genome-wide methylation analyses of 5-Aza-treated versus untreated cells identified 297 genes overexpressed in P69 and 191 genes overexpressed in M12 cells. 102 genes were upregulated in both benign and metastatic cell lines. In addition, our analyses identified the PITX2 gene as a master regulator upstream of the AR and IGF-IR genes. The PITX2 promoter was semi-methylated in P69 cells but fully methylated (i. e., silenced) in M12 cells. Epigenetic regulation of PITX2 during the course of the disease may lead to orchestrated control of the AR and IGF signaling pathways. In summary, our results provide new insights into the epigenetic changes associated with progression of prostate cancer from an organ confined, androgen-sensitive disorder to an aggressive, androgen-insensitive disease.
Collapse
Affiliation(s)
- H Schayek
- Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, Sorek R, Rechavi G. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 2012; 485:201-6. [PMID: 22575960 DOI: 10.1038/nature11112] [Citation(s) in RCA: 3097] [Impact Index Per Article: 258.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2011] [Accepted: 04/11/2012] [Indexed: 12/22/2022]
Abstract
An extensive repertoire of modifications is known to underlie the versatile coding, structural and catalytic functions of RNA, but it remains largely uncharted territory. Although biochemical studies indicate that N(6)-methyladenosine (m(6)A) is the most prevalent internal modification in messenger RNA, an in-depth study of its distribution and functions has been impeded by a lack of robust analytical methods. Here we present the human and mouse m(6)A modification landscape in a transcriptome-wide manner, using a novel approach, m(6)A-seq, based on antibody-mediated capture and massively parallel sequencing. We identify over 12,000 m(6)A sites characterized by a typical consensus in the transcripts of more than 7,000 human genes. Sites preferentially appear in two distinct landmarks--around stop codons and within long internal exons--and are highly conserved between human and mouse. Although most sites are well preserved across normal and cancerous tissues and in response to various stimuli, a subset of stimulus-dependent, dynamically modulated sites is identified. Silencing the m(6)A methyltransferase significantly affects gene expression and alternative splicing patterns, resulting in modulation of the p53 (also known as TP53) signalling pathway and apoptosis. Our findings therefore suggest that RNA decoration by m(6)A has a fundamental role in regulation of gene expression.
Collapse
Affiliation(s)
- Dan Dominissini
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D, D'Orazi G. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol Ther 2012; 13:198-205. [PMID: 22236966 DOI: 10.4161/cbt.13.4.18694] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Vimentin, a mesenchymal marker, is frequently overexpressed in epithelial carcinomas undergoing epithelial to mesenchymal transition (EMT), a condition correlated with invasiveness and poor prognosis. Therefore, vimentin is a potential molecular target for anticancer therapy. Emerging studies in experimental models underscore the functions of homeodomain-interacting protein kinase 2 (HIPK2) as potential oncosuppressor by acting as transcriptional corepressor or catalytic activator of molecules involved in apoptosis and response to antitumor drugs. However, an involvement of HIPK2 in limiting tumor invasion remains to be elucidated. This study, by starting with a microarray analysis, demonstrates that HIPK2 downregulates vimentin expression in invasive, vimentin-positive, MDA-MB-231 breast cancer cells and in the non-invasive MCF7 breast cancer cells subjected to chemical hypoxia, a drive for mesenchymal shift and tumor invasion. At functional level, vimentin downregulation by HIPK2 correlates with inhibition of breast tumor cell invasion. Together, these data show that vimentin is a novel target for HIPK2 repressor function and that HIPK2-mediated vimentin downregulation can contribute to inhibition of breast cancer cells invasion that might be applied in clinical therapy.
Collapse
Affiliation(s)
- Cristina Nodale
- Department of Experimental Oncology, Molecular Oncogenesis Laboratory, National Cancer Institute "Regina Elena", Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, Yarden Y. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 2011; 26:1582-92. [PMID: 22198386 DOI: 10.1096/fj.11-194654] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The signaling pathways that commit cells to migration are incompletely understood. We employed human mammary cells and two stimuli: epidermal growth factor (EGF), which induced cellular migration, and serum factors, which stimulated cell growth. In addition to strong activation of ERK by EGF, and AKT by serum, early transcription remarkably differed: while EGF induced early growth response-1 (EGR1), and this was required for migration, serum induced c-Fos and FosB to enhance proliferation. We demonstrate that induction of EGR1 involves ERK-mediated down-regulation of microRNA-191 and phosphorylation of the ETS2 repressor factor (ERF) repressor, which subsequently leaves the nucleus. Unexpectedly, knockdown of ERF inhibited migration, which implies migratory roles for exported ERF molecules. On the other hand, chromatin immunoprecipitation identified a subset of direct EGR1 targets, including EGR1 autostimulation and SERPINB2, whose transcription is essential for EGF-induced cell migration. In summary, EGR1 and the EGF-ERK-ERF axis emerge from our study as major drivers of growth factor-induced mammary cell migration.
Collapse
Affiliation(s)
- Gabi Tarcic
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kain D, Yagil C, Landa-Rouben N, Jacob-Hirsch J, Dor C, Yagil Y, Leor J. Abstract P228: MicroRNA Expression in Hypertension and Left Ventricular Hypertrophy in Rat. Circ Res 2011. [DOI: 10.1161/res.109.suppl_1.ap228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Heart injury and stress can cause a hypertrophic growth response in cardiac myocytes, which is characterized by an increase in cell size, enhanced protein synthesis, and activation of fetal genes, which can lead to heart failure (HF) and death. Given the emerging roles of microRNAs (miRNAs) in modulation of cellular phenotypes, we aimed to investigate miRNAs that are regulated during hypertension, left ventricular hypertrophy (LVH) and HF by using a rat model.
Methods and Results:
Male salt-sensitive (SBH/y) and salt-resistant (SBN/y) Sabra rats were obtained from the Israeli Rat Genome Center. Animals were salt-loaded with deoxycorticosterone-acetate (75 mg DOCA pellet s.c.) and 1% NaCl in drinking water for 16 weeks. Systolic blood pressure was determined by the tail-cuff method. Cardiac images were obtained using cardiac MRI using a specific small animal imaging protocol. Rats were sacrificed at different time points. miRNA expression was studied in the left ventricle using GeneChip miRNA Array (affymetrix). Expression of miRNAs related to cardiac hypertrophy or cell proliferation, including miR-132, miR-212, miR-29, miR-31and miR-205, increased more than 1.5 fold in salt-loaded SBH/y compared with salt-loaded SBN/y. In contrast, expression of MiR-182, miR-17-3p and miR-130b, known to be down-regulated in heart disease, diminished more than -1.5 fold in salt-loaded SBH/y compared with salt-loaded SBN/y.
Conclusions:
In animal model of salt-sensitive hypertension and LVH, up- and down-regulation of distinct miRNAs in the heart suggest novel therapeutic targets to prevent and reverse LVH and HF.
Collapse
Affiliation(s)
- David Kain
- Neufeld Cardiac Rsch Institute, Tel Hashomer, Israel
| | - Chana Yagil
- Laboratory for Molecular Medicine and Israeli Rat Genome Cntr, Ashkelon, Israel
| | | | | | - Chen Dor
- Sheba Cancer Rsch Cntr, Tel Hashomer, Israel
| | - Yoram Yagil
- Laboratory for Molecular Medicine and Israeli Rat Genome Cntr, Ashkelon, Israel
| | - Jonathan Leor
- Neufeld Cardiac Rsch Institute, Tel Hashomer, Israel
| |
Collapse
|
42
|
Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, Rechavi G, D'Orazi G, Givol D, Amariglio N. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 2011; 131:E562-8. [PMID: 21932419 DOI: 10.1002/ijc.26441] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Accepted: 09/05/2011] [Indexed: 02/02/2023]
Abstract
Activated p53 is necessary for tumor suppression. Homeodomain-interacting protein kinase-2 (HIPK2) is a positive regulator of functional p53. HIPK2 modulates wild-type p53 activity toward proapoptotic transcription and tumor suppression by the phosphorylation of serine 46. Knock-down of HIPK2 interferes with tumor suppression and sensitivity to chemotherapy. Combined administration of adriamycin and zinc restores activity of misfolded p53 and enables the induction of its proapoptotic and tumor suppressor functions in vitro and in vivo. We therefore looked for a cancer model where HIPK2 expression is low. MMTV-neu transgenic mice overexpressing HER2/neu, develop mammary tumors at puberty with a long latency, showing very low expression of HIPK2. Here we show that whereas these tumors are resistant to adriamycin treatment, a combination of adriamycin and zinc suppresses tumor growth in vivo in these mice, an effect evidenced by the histological features of the mammary tumors. The combined treatment of adriamycin and zinc also restores wild-type p53 conformation and induces proapoptotic transcription activity. These findings may open up new possibilities for the treatment of human cancers via the combination of zinc with chemotherapeutic agents, for a selected group of patients expressing low levels of HIPK2, with an intact p53. In addition, HIPK2 may serve as a new biomarker for tumor aggressiveness.
Collapse
Affiliation(s)
- Ofer Margalit
- Cancer Research Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 2011; 31:907-17. [PMID: 21743488 PMCID: PMC3193899 DOI: 10.1038/onc.2011.279] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.
Collapse
Affiliation(s)
- C-R Pradeep
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Buzhor E, Harari-Steinberg O, Omer D, Metsuyanim S, Jacob-Hirsch J, Noiman T, Dotan Z, Goldstein RS, Dekel B. Kidney spheroids recapitulate tubular organoids leading to enhanced tubulogenic potency of human kidney-derived cells. Tissue Eng Part A 2011; 17:2305-19. [PMID: 21542667 DOI: 10.1089/ten.tea.2010.0595] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Cell-based approaches utilizing autologous human renal cells require their isolation, expansion in vitro, and reintroduction back into the host for renal tissue regeneration. Nevertheless, human kidney epithelial cells (hKEpCs) lose their phenotype, dedifferentiate, and assume the appearance of fibroblasts after relatively few passages in culture. We hypothesized that growth conditions may influence hKEpC phenotype and function. hKEpCs retrieved from human nephrectomy tissue samples showed the ability to reproducibly form kidney spheres when grown in suspension culture developed in nonadherent conditions. Genetic labeling and time-lapse microscopy indicated, at least in part, the aggregation of hKEpCs into 3D spheroids rather than formation of pure clonally expanded spheres. Characterization of hKEpC spheroids by real-time polymerase chain reaction and FACS analysis showed upregulation of some renal developmental and "stemness" markers compared with monolayer and mostly an EpCAM(+)CD24(+)CD133(+)CD44(+) spheroid cell phenotype. Oligonucleotide microarrays, which were used to identify global transcriptional changes accompanying spheroid formation, showed predominantly upregulation of cell matrix/cell contact molecules and cellular biogenesis processes and downregulation of cell cycle, growth, and locomotion. Accordingly, hKEpC spheroids slowly proliferated as indicated by low Ki-67 staining, but when grafted in low cell numbers onto the chorioallantoic membrane (CAM) of the chick embryo, they exclusively reconstituted various renal tubular epithelia. Moreover, efficient generation of kidney spheroids was observed after long-term monolayer culture resulting in reestablishment of tubulogenic capacity upon CAM grafting. Thus, generation of a tubular organoid in hKEpC spheroids may provide a functional benefit for kidney-derived cells in vivo.
Collapse
Affiliation(s)
- Ella Buzhor
- Sheba Medical Center, Pediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Tel Hashomer, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Shuster A, Korem M, Jacob-Hirsch J, Amariglio N, Rechavi G, Rosenberg M. Microbial alcohol-conferred hemolysis is a late response to alcohol stress. FEMS Yeast Res 2011; 11:315-23. [PMID: 21276200 DOI: 10.1111/j.1567-1364.2011.00722.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
We have reported previously that growth on alcohol vapors confers hemolytic properties on certain yeast species and strains ['microbial alcohol-conferred hemolysis' (MACH)]. In a recent study, we analyzed the genetic basis of MACH in Saccharomyces cerevisiae using the EUROSCARF mutant collection. The data suggested that intact mitochondrial and respiratory chain functions are critical for the observed alcohol-mediated hemolysis. We proposed that the uncontrolled cellular uptake of alcohol results in yeast 'hyper-respiration', leading to elaboration of hemolytic molecules such as hydrogen peroxide and lytic lipids. In the current study, we have further analyzed the molecular mechanisms involved in the MACH phenomenon in S. cerevisiae, using DNA microarrays. The patterns of regulation were confirmed by quantitative reverse transcriptase PCR. The results presented here lend further support to this hypothesis, based on upregulation of the genes responsible for coping with vast amounts of hydrogen peroxide produced as a byproduct of excessive oxidation of alcohol. These results, taken together, show that alcohol-mediated hemolysis in yeast appears to be related to the overproduction of hemolytic byproducts, particularly hydrogen peroxide, which accumulates during long-term exposure of S. cerevisiae to both ethanol and n-butanol.
Collapse
Affiliation(s)
- Amir Shuster
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel-Aviv University, Ramat-Aviv, Israel
| | | | | | | | | | | |
Collapse
|
46
|
Mayo L, Levy A, Jacob-Hirsch J, Amariglio N, Rechavi G, Stein R. Bid regulates the immunological profile of murine microglia and macrophages. Glia 2010; 59:397-412. [PMID: 21264947 DOI: 10.1002/glia.21109] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2010] [Accepted: 10/18/2010] [Indexed: 11/12/2022]
Abstract
Apoptosis is a controlled cell-death process mediated inter alia by proteins of the Bcl-2 family. Some proteins previously shown to promote the apoptotic process were found to have nonapoptotic functions as well. Microglia, the resident immune cells of the central nervous system, respond to brain derangements by becoming activated to contend with the brain damage. Activated microglia can also undergo activation-induced cell death. Previous studies have addressed the role of core apoptotic proteins in the death process, but whether these proteins also play a role or not in the activation process is not been reported. Here we explore the effect of the BH3-only protein Bid on the immunological features of microglia and macrophages. Our results showed that Bid regulates both the phagocytotic activities and the inflammatory profiles of these cells. Deficiency of Bid attenuated the phagocytotic activity of primary microglia and peritoneal macrophages. It also changed the expression profile of distinct inflammation-related genes in lipopolysaccharide-activated microglia and peritoneal macrophages in vitro and in an in vivo sepsis-like paradigm. Notably, similar changes followed downregulation of Bid in the N9 microglial cell line. Cell death could not be detected in any of the systems examined. Our findings demonstrate that Bid can regulate the immunological profiles of activated microglial and macrophages, via a novel nonapoptotic activity. In view of the critical role of these cells in various pathologies, including acute and chronic brain insults, our findings suggest that impairments in Bid expression may contribute to these pathologies also via a nonapoptotic activity.
Collapse
Affiliation(s)
- Lior Mayo
- Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | | | |
Collapse
|
47
|
Solmesky L, Lefler S, Jacob-Hirsch J, Bulvik S, Rechavi G, Weil M. Serum free cultured bone marrow mesenchymal stem cells as a platform to characterize the effects of specific molecules. PLoS One 2010; 5. [PMID: 20844755 PMCID: PMC2937025 DOI: 10.1371/journal.pone.0012689] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2010] [Accepted: 08/23/2010] [Indexed: 11/18/2022] Open
Abstract
Human mesenchymal stem cells (hMSC) are easily isolated from the bone marrow by adherence to plastic surfaces. These cells show self-renewal capacity and multipotency. A unique feature of hMSC is their capacity to survive without serum. Under this condition hMSC neither proliferate nor differentiate but maintain their biological properties unaffected. Therefore, this should be a perfect platform to study the biological effects of defined molecules on these human stem cells. We show that hMSC treated for five days with retinoic acid (RA) in the absence of serum undergo several transcriptional changes causing an inhibition of ERK related pathways. We found that RA induces the loss of hMSC properties such as differentiation potential to either osteoblasts or adipocytes. We also found that RA inhibits cell cycle progression in the presence of proliferating signals such as epidermal growth factor (EGF) combined with basic fibroblast growth factor (bFGF). In the same manner, RA showed to cause a reduction in cell adhesion and cell migration. In contrast to these results, the addition of EGF+bFGF to serum free cultures was enough to upregulate ERK activity and induce hMSC proliferation and cell migration. Furthermore, the addition of these factors to differentiation specific media instead of serum was enough to induce either osteogenesis or adipogenesis. Altogether, our results show that hMSC's ability to survive without serum enables the identification of signaling factors and pathways that are involved in their stem cell biological characteristics without possible serum interferences.
Collapse
Affiliation(s)
- Leonardo Solmesky
- Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Sharon Lefler
- Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | | | - Shlomo Bulvik
- Hematology Department, Laniado Hospital, Netanya, Israel
| | - Gideon Rechavi
- Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - Miguel Weil
- Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
- * E-mail:
| |
Collapse
|
48
|
Nemlich Y, Ortenberg R, Greenberg E, Jacob-Hirsch J, Barshack I, Besser M, Schachter J, Amariglio N, Rechavi G, Markel G. 375 The role of A to I RNA editing enzymes in melanoma. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71176-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
49
|
Nagar M, Jacob-Hirsch J, Vernitsky H, Berkun Y, Ben-Horin S, Amariglio N, Bank I, Kloog Y, Rechavi G, Goldstein I. TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function. J I 2010; 184:3570-81. [DOI: 10.4049/jimmunol.0902070] [Citation(s) in RCA: 115] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
50
|
Chaluvally-Raghavan P, Zeisel A, Koestler W, Jacob-Hirsch J, Rechavi G, Domany E, Yarden Y. HER2-Associated Breast Cancer Signature Using a 3D Culture Model. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Carcinomas of the breast account for one third of all cancers occurring in woman and responsible for approximately one quarter of cancer-related deaths in females. The HER2/Neu -oncogene is amplified in 20-25% percent of human primary breast cancers and this alteration is associated with disease behaviour. Whereas signalling pathways emanating from HER2 have been characterized, much less is known about the transcriptionally regulated genes that contribute to HER2 tumorigenic effects.Materials and Methods: Normal and HER2 overexpressing mammary epithelial cells (MCF10A) were grown in extracellular matrix to form 3D structures, which allow epithelial cells to organize into structures that resemble their in vivo architecture. RNA was isolated from the 3D structures and hybridized to an Affymetrix HuGene 1.0 ST oligonucleotide array.Results: Upon HER2 overexpression, mammary epithelial cells lost their polarity and formed disorganized structures in matrigel. Using microarrays we analyzed transcriptional events responsible for the morphological changes and found that several sets of genes such as integral proteins, transcription factors, matrix proteases and chemokines were highly altered in the HER2 overexpressing group. Using gene annotation we defined molecular-pathways which are highly altered in HER2 overexpressing cells. More generally, our study proposes a mechanistic description of the processes underlying the HER2 transcriptional network.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4146.
Collapse
Affiliation(s)
| | - A. Zeisel
- 2Weizmann Institute of Science, Israel
| | - W. Koestler
- 1Weizmann Institute of Science, Israel, Israel
| | - J. Jacob-Hirsch
- 3The Chaim Sheba Medical Centre and Sackler School of Medicine, Israel
| | - G. Rechavi
- 3The Chaim Sheba Medical Centre and Sackler School of Medicine, Israel
| | - E. Domany
- 2Weizmann Institute of Science, Israel
| | - Y. Yarden
- 1Weizmann Institute of Science, Israel, Israel
| |
Collapse
|